US20220002318A1 - Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor - Google Patents
Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor Download PDFInfo
- Publication number
- US20220002318A1 US20220002318A1 US17/478,451 US202117478451A US2022002318A1 US 20220002318 A1 US20220002318 A1 US 20220002318A1 US 202117478451 A US202117478451 A US 202117478451A US 2022002318 A1 US2022002318 A1 US 2022002318A1
- Authority
- US
- United States
- Prior art keywords
- compound
- mmol
- group
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 11
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract description 4
- 229940125436 dual inhibitor Drugs 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 167
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 19
- 150000002431 hydrogen Chemical group 0.000 claims description 19
- 102000003964 Histone deacetylase Human genes 0.000 claims description 18
- 108090000353 Histone deacetylase Proteins 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- -1 3- to 8-heterocyclyl Chemical group 0.000 claims description 15
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 10
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 239000012442 inert solvent Substances 0.000 claims description 7
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940125890 compound Ia Drugs 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000009977 dual effect Effects 0.000 abstract description 6
- 150000004677 hydrates Chemical class 0.000 abstract description 5
- 239000012453 solvate Substances 0.000 abstract description 5
- 239000000651 prodrug Substances 0.000 abstract description 4
- 229940002612 prodrug Drugs 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 234
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 210
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 134
- 238000006243 chemical reaction Methods 0.000 description 124
- 239000007787 solid Substances 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- 239000011541 reaction mixture Substances 0.000 description 64
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- 239000000706 filtrate Substances 0.000 description 43
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 36
- 239000012043 crude product Substances 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 0 *[U]/C1=N/C([1*])=C(/[2*])N2C1=NC([4*])=C2[3*] Chemical compound *[U]/C1=N/C([1*])=C(/[2*])N2C1=NC([4*])=C2[3*] 0.000 description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 238000010828 elution Methods 0.000 description 20
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 20
- 238000004809 thin layer chromatography Methods 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- 238000012746 preparative thin layer chromatography Methods 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 239000012046 mixed solvent Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 239000011877 solvent mixture Substances 0.000 description 12
- 239000012295 chemical reaction liquid Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000003367 polycyclic group Chemical group 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 7
- 108010033040 Histones Proteins 0.000 description 7
- 108010016672 Syk Kinase Proteins 0.000 description 7
- 102000000551 Syk Kinase Human genes 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 7
- 238000004237 preparative chromatography Methods 0.000 description 7
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000006947 Histones Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Chemical group 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- NLXXVSKHVGDQAT-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003541 multi-stage reaction Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 102000003893 Histone acetyltransferases Human genes 0.000 description 3
- 108090000246 Histone acetyltransferases Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 2
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- URPMODQZQVVISL-KUAIMXRDSA-N CC(C)/C=C/C1=CC=CC=C1.CC(C)/C=C/C1=CC=CC=C1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C1CC1C1=CC=CC=C1.CC(C)C1CC1C1=CC=CC=C1 Chemical compound CC(C)/C=C/C1=CC=CC=C1.CC(C)/C=C/C1=CC=CC=C1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C1CC1C1=CC=CC=C1.CC(C)C1CC1C1=CC=CC=C1 URPMODQZQVVISL-KUAIMXRDSA-N 0.000 description 2
- NATNCGYPLGMTFL-UHFFFAOYSA-N CC(C)CCCCC(=O)NC1=C(N)C=CC=C1.CC(C)C[V]CC(=O)NC1=C(N)C=CC=C1 Chemical compound CC(C)CCCCC(=O)NC1=C(N)C=CC=C1.CC(C)C[V]CC(=O)NC1=C(N)C=CC=C1 NATNCGYPLGMTFL-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- JIHUQKBATKHGCP-UHFFFAOYSA-N O=C(CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1)NO Chemical compound O=C(CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1)NO JIHUQKBATKHGCP-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125801 compound 7f Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006195 histone acetylation Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 2
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NQEDSLMJTARJAI-UHFFFAOYSA-N phenol;2h-triazole Chemical compound C1=CNN=N1.OC1=CC=CC=C1 NQEDSLMJTARJAI-UHFFFAOYSA-N 0.000 description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- SGPLCUODWOWHQE-QCYMAZDCSA-N *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.BrC1=CN2C=CN=C2C(NC2=CC3=C(C=C2)N2CCN(N4CCOCC4)C[C@@H]2CO3)=N1.C.C.C.C.C.C.C.C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC4=C(C=C3)N3CCN(C5CCOCC5)C[C@@H]3CO4)C2=N1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.NC1=CC=C2C(=C1)OC[C@H]1CN(C3CCOCC3)CCN21.O=C1CCOCC1.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CN(C3CCOCC3)CCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CNCCN21 Chemical compound *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.BrC1=CN2C=CN=C2C(NC2=CC3=C(C=C2)N2CCN(N4CCOCC4)C[C@@H]2CO3)=N1.C.C.C.C.C.C.C.C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC4=C(C=C3)N3CCN(C5CCOCC5)C[C@@H]3CO4)C2=N1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.NC1=CC=C2C(=C1)OC[C@H]1CN(C3CCOCC3)CCN21.O=C1CCOCC1.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CN(C3CCOCC3)CCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CNCCN21 SGPLCUODWOWHQE-QCYMAZDCSA-N 0.000 description 1
- HMTVAFOJOGSCHJ-RBTLYZQTSA-N *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC(=O)N1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CC(=O)N1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.ClCCl.NC1=CC=C2C(=C1)OC[C@H]1CN(C(=O)C(F)(F)F)CCN21.O=C(N1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1)C(F)(F)F.O=C(O)C(F)(F)F.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21 Chemical compound *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC(=O)N1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CC(=O)N1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.ClCCl.NC1=CC=C2C(=C1)OC[C@H]1CN(C(=O)C(F)(F)F)CCN21.O=C(N1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1)C(F)(F)F.O=C(O)C(F)(F)F.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21 HMTVAFOJOGSCHJ-RBTLYZQTSA-N 0.000 description 1
- RAWOJHKNEZCSJP-ZYJWBBBISA-N *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC(C)(C)OC(=O)N1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCS(=O)(=O)N1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCS(=O)(=O)N1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCS(=O)(=O)N1CCN2C3=CC=C(N)C=C3OC[C@H]2C1.CCS(=O)(=O)N1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1 Chemical compound *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC(C)(C)OC(=O)N1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCS(=O)(=O)N1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCS(=O)(=O)N1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCS(=O)(=O)N1CCN2C3=CC=C(N)C=C3OC[C@H]2C1.CCS(=O)(=O)N1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1 RAWOJHKNEZCSJP-ZYJWBBBISA-N 0.000 description 1
- QYOGJJODQNCRAV-OSUXVRRZSA-N *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CN1CCC(=O)CC1.CN1CCC(N2CCN3C4=C(C=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4)OC[C@H]3C2)CC1.CN1CCC(N2CCN3C4=CC=C(N)C=C4OC[C@H]3C2)CC1.CN1CCC(N2CCN3C4=CC=C([N+](=O)[O-])C=C4OC[C@H]3C2)CC1.CN1CCN(N2CCN3C4=C(C=C(NC5=NC(Br)=CN6C=CN=C56)C=C4)OC[C@H]3C2)CC1.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CNCCN21 Chemical compound *.*.*.*.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CN1CCC(=O)CC1.CN1CCC(N2CCN3C4=C(C=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4)OC[C@H]3C2)CC1.CN1CCC(N2CCN3C4=CC=C(N)C=C4OC[C@H]3C2)CC1.CN1CCC(N2CCN3C4=CC=C([N+](=O)[O-])C=C4OC[C@H]3C2)CC1.CN1CCN(N2CCN3C4=C(C=C(NC5=NC(Br)=CN6C=CN=C56)C=C4)OC[C@H]3C2)CC1.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CNCCN21 QYOGJJODQNCRAV-OSUXVRRZSA-N 0.000 description 1
- XXHOJOFKENKMDW-ZTFBWZQMSA-N *.*.*.*.C.C.C.C.C.C.C1=NNC2=C1/C=C\C(C1=CN3/C=C\N=C/3C(NC3=C\C4=C(\C=C/3)N3CCN(C5CC5)C[C@@H]3CO4)=N1)=C/2.CCN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1.CN1CCC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OC[C@H]3C2)CC1.FC(F)(F)CN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1 Chemical compound *.*.*.*.C.C.C.C.C.C.C1=NNC2=C1/C=C\C(C1=CN3/C=C\N=C/3C(NC3=C\C4=C(\C=C/3)N3CCN(C5CC5)C[C@@H]3CO4)=N1)=C/2.CCN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1.CN1CCC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OC[C@H]3C2)CC1.FC(F)(F)CN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1 XXHOJOFKENKMDW-ZTFBWZQMSA-N 0.000 description 1
- DAMRZDUWPAVSQQ-LMCRVBAOSA-N *.*.*.*.C1=NNC2=C1/C=C\C(C1=CN3/C=C\N=C/3C(NC3=C/C4=C(/C=C/3)N3CCN(C5CC5)C[C@@H]3CO4)=N1)=C/2.CCN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1.CCN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1.CN1CCC(N2CCN3C4=CC=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)C=C4OC[C@H]3C2)CC1 Chemical compound *.*.*.*.C1=NNC2=C1/C=C\C(C1=CN3/C=C\N=C/3C(NC3=C/C4=C(/C=C/3)N3CCN(C5CC5)C[C@@H]3CO4)=N1)=C/2.CCN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1.CCN1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C/3)OC[C@H]2C1.CN1CCC(N2CCN3C4=CC=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)C=C4OC[C@H]3C2)CC1 DAMRZDUWPAVSQQ-LMCRVBAOSA-N 0.000 description 1
- VHXWMIVEKJVDRD-OWCJHIMKSA-N *.*.*.C.C.C.C.C1=CC2=C(C=C1C1=CN3/C=C\N=C/3C(NC3=CC=C4C(=C3)OC[C@@H]3CN4CCN(C4CCOCC4)C3)=N1)CN=C2.CCS(=O)(=O)N1CCN2C3=C\C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C\3OC[C@H]2C1.O=C(N1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)\C=C/3)OC[C@H]2C1)C(F)(F)F Chemical compound *.*.*.C.C.C.C.C1=CC2=C(C=C1C1=CN3/C=C\N=C/3C(NC3=CC=C4C(=C3)OC[C@@H]3CN4CCN(C4CCOCC4)C3)=N1)CN=C2.CCS(=O)(=O)N1CCN2C3=C\C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C\3OC[C@H]2C1.O=C(N1CCN2C3=C(/C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)\C=C/3)OC[C@H]2C1)C(F)(F)F VHXWMIVEKJVDRD-OWCJHIMKSA-N 0.000 description 1
- NDCQOAZLEGINSF-MSEYTYONSA-N *.*.BrC1=CN2C=CN=C2C(Br)=N1.BrC1=CN2C=CN=C2C(NC2=CC3=C(C=C2)N2CCN(C4CC4)C[C@@H]2CO3)=N1.C.C.C.C.C.C.C.C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC4=C(C=C3)N3CCN(C5CC5)C[C@@H]3CO4)C2=N1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCOC1(O[Si](C)(C)C)CC1.NC1=CC=C2C(=C1)OC[C@H]1CN(C3CC3)CCN21.O=C(O)C(F)(F)F.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CN(C3CC3)CCN21 Chemical compound *.*.BrC1=CN2C=CN=C2C(Br)=N1.BrC1=CN2C=CN=C2C(NC2=CC3=C(C=C2)N2CCN(C4CC4)C[C@@H]2CO3)=N1.C.C.C.C.C.C.C.C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC4=C(C=C3)N3CCN(C5CC5)C[C@@H]3CO4)C2=N1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCOC1(O[Si](C)(C)C)CC1.NC1=CC=C2C(=C1)OC[C@H]1CN(C3CC3)CCN21.O=C(O)C(F)(F)F.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CN(C3CC3)CCN21 NDCQOAZLEGINSF-MSEYTYONSA-N 0.000 description 1
- ZTTAUHUTYZFCNY-RCTXGPRNSA-N *.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.C1CCOC1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCN1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCN1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.NC1=CC=C2C(=C1)OC[C@H]1CN(CC(F)(F)F)CCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CN(CC(F)(F)F)CCN21 Chemical compound *.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.C1CCOC1.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCN1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCN1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.NC1=CC=C2C(=C1)OC[C@H]1CN(CC(F)(F)F)CCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CN(CC(F)(F)F)CCN21 ZTTAUHUTYZFCNY-RCTXGPRNSA-N 0.000 description 1
- CSUPXGRMHLATKZ-RZJVTLDQSA-N *.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCN1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCN1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCN1CCN2C3=CC=C(N)C=C3OC[C@H]2C1.CCN1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1.O=C(O)C(F)(F)F.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21 Chemical compound *.*.BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.CCN1CCN2C3=C(C=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCN1CCN2C3=C(C=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)OC[C@H]2C1.CCN1CCN2C3=CC=C(N)C=C3OC[C@H]2C1.CCN1CCN2C3=CC=C([N+](=O)[O-])C=C3OC[C@H]2C1.O=C(O)C(F)(F)F.O=[N+]([O-])C1=CC=C2C(=C1)OC[C@H]1CCCCN21 CSUPXGRMHLATKZ-RZJVTLDQSA-N 0.000 description 1
- UYFLTLKURNEJDH-SEOWUYLMSA-N *.*.C1=NNC2=C1/C=C\C(C1=CN3/C=C\N=C/3C(NC3=CC=C4C(=C3)OC[C@H]3CN(C5CCOCC5)CCN43)=N1)=C/2.CCS(=O)(=O)N1CCN2C3=CC=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)C=C3OC[C@H]2C1.NC(=O)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)C=C3)CC2)C=C1.O.O=C(CO)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=C/C5=C(C=NN5)/C=C\4)=CN4/C=C\N=C\34)C=C2)CC1 Chemical compound *.*.C1=NNC2=C1/C=C\C(C1=CN3/C=C\N=C/3C(NC3=CC=C4C(=C3)OC[C@H]3CN(C5CCOCC5)CCN43)=N1)=C/2.CCS(=O)(=O)N1CCN2C3=CC=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)C=C3OC[C@H]2C1.NC(=O)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)C=C3)CC2)C=C1.O.O=C(CO)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=C/C5=C(C=NN5)/C=C\4)=CN4/C=C\N=C\34)C=C2)CC1 UYFLTLKURNEJDH-SEOWUYLMSA-N 0.000 description 1
- DBCMHMMRIQVNOT-JFFKZYFRSA-N *.CC(=O)N1CCN2C3=C(C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)C=C3)OC[C@H]2C1.NC1=C(NC(=O)C2=CC=CC(C3=CN4/C=C\N=C/4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=CC=C1.O=C(/C=C/C1=CC=C(C2=CN3/C=C\N=C/3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1)CO.O=C(NO)C1=CC=C(NC2=NC(C3=C/C4=C(C=NN4)/C=C\3)=CN3/C=C\N=C\23)C=C1 Chemical compound *.CC(=O)N1CCN2C3=C(C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)C=C3)OC[C@H]2C1.NC1=C(NC(=O)C2=CC=CC(C3=CN4/C=C\N=C/4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=CC=C1.O=C(/C=C/C1=CC=C(C2=CN3/C=C\N=C/3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1)CO.O=C(NO)C1=CC=C(NC2=NC(C3=C/C4=C(C=NN4)/C=C\3)=CN3/C=C\N=C\23)C=C1 DBCMHMMRIQVNOT-JFFKZYFRSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 1
- MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- AXHVEQQLKVIZLO-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]benzoic acid Chemical compound CCC(C)(C)CC1=CNC(CCC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)=N1 AXHVEQQLKVIZLO-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- ZTTWQKYKGNLCCA-UHFFFAOYSA-N 2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine Chemical compound N1C2=CC=CC=C2N=C(N)C2=C1SC(C)=C2 ZTTWQKYKGNLCCA-UHFFFAOYSA-N 0.000 description 1
- LTBWKAYPXIIVPC-UHFFFAOYSA-N 3-bromo-9h-carbazole Chemical compound C1=CC=C2C3=CC(Br)=CC=C3NC2=C1 LTBWKAYPXIIVPC-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- CZGCEKJOLUNIFY-UHFFFAOYSA-N 4-Chloronitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1 CZGCEKJOLUNIFY-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- WMKDUJVLNZANRN-UHFFFAOYSA-N 6-bromo-1h-indazole Chemical compound BrC1=CC=C2C=NNC2=C1 WMKDUJVLNZANRN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- HBPSXMWJJMOEII-UHFFFAOYSA-M BrC1=CC2=C(C=C1)C=NC2.BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.C.C.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CCOC(=O)CCCCCCBr.CCOC(=O)CCCCCCN1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.CCOC(=O)CCCCCCN1N=CC2=C1C=C(Br)C=C2.CCOC(=O)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O.O=C(O)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O[Na] Chemical compound BrC1=CC2=C(C=C1)C=NC2.BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.C.C.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CCOC(=O)CCCCCCBr.CCOC(=O)CCCCCCN1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.CCOC(=O)CCCCCCN1N=CC2=C1C=C(Br)C=C2.CCOC(=O)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O.O=C(O)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O[Na] HBPSXMWJJMOEII-UHFFFAOYSA-M 0.000 description 1
- XTPMLQXANVXWPR-UHFFFAOYSA-L BrC1=CN2C=CN=C2C(Br)=N1.BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.C.C.C.C.C.C.C.C.C.C1COCCN1.CC1(C)OB(C2=CC(C(=O)NC3=CC=CC=C3N)=CC=C2)OC1(C)C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.NC1=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=CC=C1.NC1=CC=C(Cl)C=C1.NC1=CC=C(N2CCOCC2)C=C1.NC1=CC=C(N2CCOCC2)C=C1.NC1=CC=CC=C1N.O=COO[K].O=COO[K].[KH].[KH] Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.C.C.C.C.C.C.C.C.C.C1COCCN1.CC1(C)OB(C2=CC(C(=O)NC3=CC=CC=C3N)=CC=C2)OC1(C)C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.NC1=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=CC=C1.NC1=CC=C(Cl)C=C1.NC1=CC=C(N2CCOCC2)C=C1.NC1=CC=C(N2CCOCC2)C=C1.NC1=CC=CC=C1N.O=COO[K].O=COO[K].[KH].[KH] XTPMLQXANVXWPR-UHFFFAOYSA-L 0.000 description 1
- WWXWNVFCABETNP-UHFFFAOYSA-N BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.COC(=O)C1=CC=C(C=O)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(N)C=C3)CC2)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(N)C=C3)CC2)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)CC2)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)CC2)C=C1.NC1=CC=C(N2CCNCC2)C=C1.O=C(NO)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)CC2)C=C1 Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.COC(=O)C1=CC=C(C=O)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(N)C=C3)CC2)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(N)C=C3)CC2)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(Br)=CN5C=CN=C45)C=C3)CC2)C=C1.COC(=O)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)CC2)C=C1.NC1=CC=C(N2CCNCC2)C=C1.O=C(NO)C1=CC=C(CN2CCN(C3=CC=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3)CC2)C=C1 WWXWNVFCABETNP-UHFFFAOYSA-N 0.000 description 1
- QECGDVQULVLRPI-UHFFFAOYSA-N BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C(N)C=C2)CC1.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(Br)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1.COC(=O)CCCCCCC(=O)O.O=[N+]([O-])C1=CC=C(N2CCNCC2)C=C1 Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C(N)C=C2)CC1.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(Br)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCCCCC(=O)N1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1.COC(=O)CCCCCCC(=O)O.O=[N+]([O-])C1=CC=C(N2CCNCC2)C=C1 QECGDVQULVLRPI-UHFFFAOYSA-N 0.000 description 1
- JACDUSDGLZGFEJ-UHFFFAOYSA-O BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.NC1=CC=C(C(=O)NOC2CCCCO2)C=C1.NC1=CC=C(C(=O)O)C=C1.O=C(NO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.O=C(NOC1CCCCO1)C1=CC=C(NC2=NC(Br)=CN3C=CN=C23)C=C1.O=C(NOC1CCCCO1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.[H+] Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.C.C.C.C.C.C.C.CC1(C)OB(C2=CC3=C(C=C2)C=NC3)OC1(C)C.NC1=CC=C(C(=O)NOC2CCCCO2)C=C1.NC1=CC=C(C(=O)O)C=C1.O=C(NO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.O=C(NOC1CCCCO1)C1=CC=C(NC2=NC(Br)=CN3C=CN=C23)C=C1.O=C(NOC1CCCCO1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.[H+] JACDUSDGLZGFEJ-UHFFFAOYSA-O 0.000 description 1
- CILJBBLEKVZGAO-UHFFFAOYSA-N BrC1=CN2C=CN=C2C(Br)=N1.C.C.CC(C)(C)OC(=O)N1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.COC(=O)CCCC(=O)N1CCN(C2=CC=C(N)C=C2)CC1.COC(=O)CCCC(=O)N1CCN(C2=CC=C(NC3=NC(Br)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCC(=O)N1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1.COC(=O)CCCC(=O)O.O=[N+]([O-])C1=CC=C(N2CCCCC2)C=C1 Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.C.C.CC(C)(C)OC(=O)N1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.COC(=O)CCCC(=O)N1CCN(C2=CC=C(N)C=C2)CC1.COC(=O)CCCC(=O)N1CCN(C2=CC=C(NC3=NC(Br)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1.COC(=O)CCCC(=O)N1CCN(C2=CC=C([N+](=O)[O-])C=C2)CC1.COC(=O)CCCC(=O)O.O=[N+]([O-])C1=CC=C(N2CCCCC2)C=C1 CILJBBLEKVZGAO-UHFFFAOYSA-N 0.000 description 1
- FCKIOMXBDIYEGR-UHFFFAOYSA-N BrC1=CN2C=CN=C2C(Br)=N1.C.CC(C)(C)OC(=O)N1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.CI.COC(=O)C1=CC=C(N(C)CCCN(C)C2=CC=C(NC3=NC(Br)=CN4C=CN=C34)C=C2)C=C1.COC(=O)C1=CN=C(Cl)N=C1.COC(=O)C1=CN=C(N(C)CCN(C)C2=CC=C(N)C=C2)N=C1.COC(=O)C1=CN=C(N(C)CCN(C)C2=CC=C([N+](=O)[O-])C=C2)N=C1.COC(=O)C1=CN=C(NCCNC2=CC=C([N+](=O)[O-])C=C2)N=C1.NCCN.NCCNC1=CC=C([N+](=O)[O-])C=C1.O=[N+]([O-])C1=CC=C(Br)C=C1 Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.C.CC(C)(C)OC(=O)N1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.CI.COC(=O)C1=CC=C(N(C)CCCN(C)C2=CC=C(NC3=NC(Br)=CN4C=CN=C34)C=C2)C=C1.COC(=O)C1=CN=C(Cl)N=C1.COC(=O)C1=CN=C(N(C)CCN(C)C2=CC=C(N)C=C2)N=C1.COC(=O)C1=CN=C(N(C)CCN(C)C2=CC=C([N+](=O)[O-])C=C2)N=C1.COC(=O)C1=CN=C(NCCNC2=CC=C([N+](=O)[O-])C=C2)N=C1.NCCN.NCCNC1=CC=C([N+](=O)[O-])C=C1.O=[N+]([O-])C1=CC=C(Br)C=C1 FCKIOMXBDIYEGR-UHFFFAOYSA-N 0.000 description 1
- XSITZBPLDMJRDC-UHFFFAOYSA-M BrC1=CN2C=CN=C2C(Br)=N1.C.CC(C)(C)OC(=O)N1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.CI.COC(=O)CCCCCCN.COC(=O)CCCCCCN(C)C1=CC=C(N)C=C1.COC(=O)CCCCCCN(C)C1=CC=C(NC2=NC(Br)=CN3C=CN=C23)C=C1.COC(=O)CCCCCCN(C)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NN4C(=O)OC(C)(C)C)=CN3C=CN=C23)C=C1.COC(=O)CCCCCCN(C)C1=CC=C([N+](=O)[O-])C=C1.COC(=O)CCCCCCNC1=CC=C([N+](=O)[O-])C=C1.Cl.O.O=[N+]([O-])C1=CC=C(Br)C=C1.O[Na] Chemical compound BrC1=CN2C=CN=C2C(Br)=N1.C.CC(C)(C)OC(=O)N1N=CC2=C1C=C(B1OC(C)(C)C(C)(C)O1)C=C2.CI.COC(=O)CCCCCCN.COC(=O)CCCCCCN(C)C1=CC=C(N)C=C1.COC(=O)CCCCCCN(C)C1=CC=C(NC2=NC(Br)=CN3C=CN=C23)C=C1.COC(=O)CCCCCCN(C)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NN4C(=O)OC(C)(C)C)=CN3C=CN=C23)C=C1.COC(=O)CCCCCCN(C)C1=CC=C([N+](=O)[O-])C=C1.COC(=O)CCCCCCNC1=CC=C([N+](=O)[O-])C=C1.Cl.O.O=[N+]([O-])C1=CC=C(Br)C=C1.O[Na] XSITZBPLDMJRDC-UHFFFAOYSA-M 0.000 description 1
- HLQCAOSDFAKRLO-UHFFFAOYSA-M BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.C1=CN2C=C(C3=CCCNC3)N=C(NC3=CC=C(N4CCOCC4)C=C3)C2=N1.CC(C)(C)OC(=O)N1CCC=C(B2OC(C)(C)C(C)(C)O2)C1.CC(C)(C)OC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.COC(=O)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.COC(=O)CCCCC(=O)O.O.O[Na] Chemical compound BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.C1=CN2C=C(C3=CCCNC3)N=C(NC3=CC=C(N4CCOCC4)C=C3)C2=N1.CC(C)(C)OC(=O)N1CCC=C(B2OC(C)(C)C(C)(C)O2)C1.CC(C)(C)OC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.COC(=O)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.COC(=O)CCCCC(=O)O.O.O[Na] HLQCAOSDFAKRLO-UHFFFAOYSA-M 0.000 description 1
- GNMHDHDKDPBAGZ-UHFFFAOYSA-N BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.CC1(C)OB(C2=CC(C(=O)O)=CC=C2)OC1(C)C.NC1=CC=C(C(=O)NOC2CCCCO2)C=C1.O=C(NO)C1=CC=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=C1.O=C(NOC1CCCCO1)C1=CC=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=C1.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 Chemical compound BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.CC1(C)OB(C2=CC(C(=O)O)=CC=C2)OC1(C)C.NC1=CC=C(C(=O)NOC2CCCCO2)C=C1.O=C(NO)C1=CC=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=C1.O=C(NOC1CCCCO1)C1=CC=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=C1.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 GNMHDHDKDPBAGZ-UHFFFAOYSA-N 0.000 description 1
- MHNKUYMIQNQKFB-FHWKDNGDSA-N BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.CC1(C)OB(C2=CC=C(/C=C/C(=O)O)C=C2)OC1(C)C.O=C(/C=C/C1=CC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1)CO.O=C(/C=C/C1=CC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1)COC1CCCCO1.O=C(O)/C=C/C1=CC=C(Br)C=C1.O=C(O)/C=C/C1=CC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 Chemical compound BrC1=CN2C=CN=C2C(NC2=CC=C(N3CCOCC3)C=C2)=N1.CC1(C)OB(C2=CC=C(/C=C/C(=O)O)C=C2)OC1(C)C.O=C(/C=C/C1=CC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1)CO.O=C(/C=C/C1=CC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1)COC1CCCCO1.O=C(O)/C=C/C1=CC=C(Br)C=C1.O=C(O)/C=C/C1=CC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C=C1 MHNKUYMIQNQKFB-FHWKDNGDSA-N 0.000 description 1
- DNWYCHNCHMGYLQ-UHFFFAOYSA-N C.C.C.CN(CCCCCCC(=O)CO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCCCCCC(=O)COC1CCCCO1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCCCCCC(=O)O)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1 Chemical compound C.C.C.CN(CCCCCCC(=O)CO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCCCCCC(=O)COC1CCCCO1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCCCCCC(=O)O)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1 DNWYCHNCHMGYLQ-UHFFFAOYSA-N 0.000 description 1
- DFUDANIYJMITBM-UHFFFAOYSA-N C.C.C.NOC1CCCCO1.O=C(CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)COC1CCCCO1.O=C(CO)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1.O=C(O)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1 Chemical compound C.C.C.NOC1CCCCO1.O=C(CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)COC1CCCCO1.O=C(CO)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1.O=C(O)CCCCCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1 DFUDANIYJMITBM-UHFFFAOYSA-N 0.000 description 1
- ZPWBKNURXSRCRH-UHFFFAOYSA-N C.CC(C)C(=O)NC1=C(N)C=CC=C1.CNC(=O)C(C)C.CONC(=O)C(C)C Chemical compound C.CC(C)C(=O)NC1=C(N)C=CC=C1.CNC(=O)C(C)C.CONC(=O)C(C)C ZPWBKNURXSRCRH-UHFFFAOYSA-N 0.000 description 1
- HWIWEIHDQJXOIK-UHFFFAOYSA-N C.CN(CCOCCC(=O)NO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCOCCC(=O)NOC1CCCCO1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCOCCC(=O)O)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1 Chemical compound C.CN(CCOCCC(=O)NO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCOCCC(=O)NOC1CCCCO1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCOCCC(=O)O)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1 HWIWEIHDQJXOIK-UHFFFAOYSA-N 0.000 description 1
- WMPFJNYKKAMKID-UHFFFAOYSA-M C.CO.COC(=O)CCCCCCN.COC(=O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.Cl.NOC1CCCCO1.O.O=C(CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1)NOC1CCCCO1.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=CC(F)(F)F.O[Na] Chemical compound C.CO.COC(=O)CCCCCCN.COC(=O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.Cl.NOC1CCCCO1.O.O=C(CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1)NOC1CCCCO1.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=CC(F)(F)F.O[Na] WMPFJNYKKAMKID-UHFFFAOYSA-M 0.000 description 1
- DOIQHPUDYVMFQQ-UHFFFAOYSA-N C.CO.NOC1CCCCO1.O=C(CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1)NOC1CCCCO1.O=C(CO)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.O=C(O)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.O=CC(F)(F)F Chemical compound C.CO.NOC1CCCCO1.O=C(CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1)NOC1CCCCO1.O=C(CO)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.O=C(O)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1.O=CC(F)(F)F DOIQHPUDYVMFQQ-UHFFFAOYSA-N 0.000 description 1
- WRIIPUZFLYKKGO-UHFFFAOYSA-N C.NC1=C(N)C=CC=C1.NC1=CC=CC=C1NC(=O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 Chemical compound C.NC1=C(N)C=CC=C1.NC1=CC=CC=C1NC(=O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 WRIIPUZFLYKKGO-UHFFFAOYSA-N 0.000 description 1
- LXAWLPQAJXPMHW-UHFFFAOYSA-N C1=CC(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)=CC=N1.C1=CC(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)=CN=C1.C1=CC=C(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)C=C1.C1=CN=C(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)C=C1 Chemical compound C1=CC(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)=CC=N1.C1=CC(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)=CN=C1.C1=CC=C(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)C=C1.C1=CN=C(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)C=C1 LXAWLPQAJXPMHW-UHFFFAOYSA-N 0.000 description 1
- IBMOLVVBNDPNOI-UHFFFAOYSA-N C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CC=N1.C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CO1.C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CS1.CN1C=C(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)N=N1 Chemical compound C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CC=N1.C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CO1.C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CS1.CN1C=C(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)N=N1 IBMOLVVBNDPNOI-UHFFFAOYSA-N 0.000 description 1
- RZKHNBRUUFHJML-UHFFFAOYSA-N C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CN=C1.C1=CC=C(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)C=C1.C1=CN=C(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)C=C1.CS(=O)(=O)N1CCN2C3=C\C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C\3OCC2C1 Chemical compound C1=CC(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)=CN=C1.C1=CC=C(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)C=C1.C1=CN=C(N2CCN3C4=C\C=C(NC5=NC(C6=C/C7=C(C=NN7)/C=C\6)=CN6/C=C\N=C\56)/C=C\4OCC3C2)C=C1.CS(=O)(=O)N1CCN2C3=C\C=C(NC4=NC(C5=C/C6=C(C=NN6)/C=C\5)=CN5/C=C\N=C\45)/C=C\3OCC2C1 RZKHNBRUUFHJML-UHFFFAOYSA-N 0.000 description 1
- IPECMDNFGXZHLP-UHFFFAOYSA-N C1=CC2=C(C=C1)CCC2.C1=CC2=C(C=C1)CCCC2.C1CC2(C1)CCC2.C1CC2CC(C1)C2.C1CC2CC2C1.C1CC2CCC(C1)C2.C1CC2CCC1CC2.C1CC2CCCC2C1.C1CCC2CCC2C1.C1CCC2CCCCC2C1.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C1CC1.CC(C)(C)C1CC2=C(CCC2)C1.CC(C)(C)C1CCC1.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C Chemical compound C1=CC2=C(C=C1)CCC2.C1=CC2=C(C=C1)CCCC2.C1CC2(C1)CCC2.C1CC2CC(C1)C2.C1CC2CC2C1.C1CC2CCC(C1)C2.C1CC2CCC1CC2.C1CC2CCCC2C1.C1CCC2CCC2C1.C1CCC2CCCCC2C1.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C1CC1.CC(C)(C)C1CC2=C(CCC2)C1.CC(C)(C)C1CCC1.CC(C)(C)C1CCCC1.CC(C)(C)C1CCCCC1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C IPECMDNFGXZHLP-UHFFFAOYSA-N 0.000 description 1
- RBWBIJOZVDTQHV-UHFFFAOYSA-N C1=CC2=C(C=C1)NCCC2.C1=CC2=C(C=C1)OCCN2.C1=CC2=C(CCCC2)N=C1.C1=NC2=C(CCCC2)O1.C1CC2(C1)CNC2.C1CC2(C1)COC2.C1CC2CCNC2C1.C1CC2CNCC2C1.C1CC2CNCC2C1.C1CCN2CCC2C1.C1CCNC1.C1CCOC1.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)N1CC2CC2C1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.O=C1CCCC2CCCN12.O=C1CNCC2=CC=CN12.O=C1CNCC2CCCN12.O=S1(=O)CCCC1 Chemical compound C1=CC2=C(C=C1)NCCC2.C1=CC2=C(C=C1)OCCN2.C1=CC2=C(CCCC2)N=C1.C1=NC2=C(CCCC2)O1.C1CC2(C1)CNC2.C1CC2(C1)COC2.C1CC2CCNC2C1.C1CC2CNCC2C1.C1CC2CNCC2C1.C1CCN2CCC2C1.C1CCNC1.C1CCOC1.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)C.CC(C)(C)N1CC2CC2C1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.O=C1CCCC2CCCN12.O=C1CNCC2=CC=CN12.O=C1CNCC2CCCN12.O=S1(=O)CCCC1 RBWBIJOZVDTQHV-UHFFFAOYSA-N 0.000 description 1
- OCWGPUOHYCSKPS-UHFFFAOYSA-N C1=CC=C2C(=C1)CC1=C2C=CC=C1.C1=CC=C2C=CC=CC2=C1.C1=CC=C2CCCC2=C1.C1=CC=C2CCCCC2=C1.C1=CC=CC=C1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C Chemical compound C1=CC=C2C(=C1)CC1=C2C=CC=C1.C1=CC=C2C=CC=CC2=C1.C1=CC=C2CCCC2=C1.C1=CC=C2CCCCC2=C1.C1=CC=CC=C1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C OCWGPUOHYCSKPS-UHFFFAOYSA-N 0.000 description 1
- MVCIYDVRAADIMQ-UHFFFAOYSA-N C1=CC=C2C(=C1)CCC1CCCCN21.CC.CC.CC(C)C Chemical compound C1=CC=C2C(=C1)CCC1CCCCN21.CC.CC.CC(C)C MVCIYDVRAADIMQ-UHFFFAOYSA-N 0.000 description 1
- NWNGJEQQIODEIG-UHFFFAOYSA-N C1=CC=C2C(=C1)OC[C+]1CNCCN21.C1=CC=C2C(=C1)OC[C+]1COCCN21.C1=CC=C2CNCCC2=C1.C1=CC=C2NCCCC2=C1.C1=CC=C2OCCNC2=C1.C1=CN2C=CN=C2C=N1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.O=C1CNC[C+]2COC3=CC=CC=C3N12 Chemical compound C1=CC=C2C(=C1)OC[C+]1CNCCN21.C1=CC=C2C(=C1)OC[C+]1COCCN21.C1=CC=C2CNCCC2=C1.C1=CC=C2NCCCC2=C1.C1=CC=C2OCCNC2=C1.C1=CN2C=CN=C2C=N1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.O=C1CNC[C+]2COC3=CC=CC=C3N12 NWNGJEQQIODEIG-UHFFFAOYSA-N 0.000 description 1
- YDEHPJVJWAIHDH-UHFFFAOYSA-N C1=CC=C2CN=CC2=C1.C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CCC2=C1.C1=CC=C2OC=NC2=C1.C1=CC=C2OC=NC2=C1.C1=CC=NC=C1.C1=CC=NC=C1.C1=CN=C2C(=C1)CC1=C2C=CC=C1.C1=CN=C2CCCC2=C1.C1=CN=C2CCCCC2=C1.C1=CN=CN=C1.C1=COC=N1.C1=CSC=N1.C1=NC=C2N=COC2=C1.C1=NN=CO1.C1=NNNC1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.O=C1C=CC2=CC=CC=C2N1.O=C1CC2=CC=CC=C2C1.O=C1CC2=CC=CC=C2O1 Chemical compound C1=CC=C2CN=CC2=C1.C1=CC=C2N=CC=CC2=C1.C1=CC=C2N=CCC2=C1.C1=CC=C2OC=NC2=C1.C1=CC=C2OC=NC2=C1.C1=CC=NC=C1.C1=CC=NC=C1.C1=CN=C2C(=C1)CC1=C2C=CC=C1.C1=CN=C2CCCC2=C1.C1=CN=C2CCCCC2=C1.C1=CN=CN=C1.C1=COC=N1.C1=CSC=N1.C1=NC=C2N=COC2=C1.C1=NN=CO1.C1=NNNC1.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.CC(C)C.O=C1C=CC2=CC=CC=C2N1.O=C1CC2=CC=CC=C2C1.O=C1CC2=CC=CC=C2O1 YDEHPJVJWAIHDH-UHFFFAOYSA-N 0.000 description 1
- NXXQXTBMTWXLBO-UHFFFAOYSA-N C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC=C4C(=C3)OCC3CN(C5=COC=C5)CCN43)C2=N1.C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC=C4C(=C3)OCC3CN(C5=CSC=C5)CCN43)C2=N1.CN1C=C(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)N=N1 Chemical compound C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC=C4C(=C3)OCC3CN(C5=COC=C5)CCN43)C2=N1.C1=CN2C=C(C3=CC4=C(C=C3)C=NC4)N=C(NC3=CC=C4C(=C3)OCC3CN(C5=CSC=C5)CCN43)C2=N1.CN1C=C(N2CCN3C4=CC=C(NC5=NC(C6=CC7=C(C=C6)C=NC7)=CN6C=CN=C56)C=C4OCC3C2)N=N1 NXXQXTBMTWXLBO-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- QDHOBONUIOJKTI-UHFFFAOYSA-N CC(C)(C)C1=CC=C(N2CCOCC2)C=C1 Chemical compound CC(C)(C)C1=CC=C(N2CCOCC2)C=C1 QDHOBONUIOJKTI-UHFFFAOYSA-N 0.000 description 1
- MKAIFWYJNVWNIH-UHFFFAOYSA-N CC(C)C(=O)NC1=C(N)C=CC=C1.CC(C)C(=O)NO.CONC(=O)C(C)C Chemical compound CC(C)C(=O)NC1=C(N)C=CC=C1.CC(C)C(=O)NO.CONC(=O)C(C)C MKAIFWYJNVWNIH-UHFFFAOYSA-N 0.000 description 1
- PNMKRXJSMFUFNX-UHFFFAOYSA-N CC(C)CCC[V]CC(=O)NO.CC(C)CCC[V]CC(=O)NOC1CCCCO1.CC(C)CCC[V]CC(=O)O.COC(=O)C[V]CCCC(C)C Chemical compound CC(C)CCC[V]CC(=O)NO.CC(C)CCC[V]CC(=O)NOC1CCCCO1.CC(C)CCC[V]CC(=O)O.COC(=O)C[V]CCCC(C)C PNMKRXJSMFUFNX-UHFFFAOYSA-N 0.000 description 1
- LDBBVDXBNIFOCN-UHFFFAOYSA-N CC(C)C[V]CC(=O)NO.CC(C)C[V]CC(=O)NOC1CCCCO1.CC(C)C[V]CC(=O)O.COC(=O)C[V]CC(C)C Chemical compound CC(C)C[V]CC(=O)NO.CC(C)C[V]CC(=O)NOC1CCCCO1.CC(C)C[V]CC(=O)O.COC(=O)C[V]CC(C)C LDBBVDXBNIFOCN-UHFFFAOYSA-N 0.000 description 1
- IXTRUHYQJCQEJA-UHFFFAOYSA-N CN(CCCCCCC(=O)CO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.NC1=CC=CC=C1NC(=O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1)NO.O=C(CO)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1 Chemical compound CN(CCCCCCC(=O)CO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.NC1=CC=CC=C1NC(=O)CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(CCCCCCNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1)NO.O=C(CO)CCCCC(=O)N1CCC=C(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)C1 IXTRUHYQJCQEJA-UHFFFAOYSA-N 0.000 description 1
- YIDBICVNWSIVPT-UHFFFAOYSA-N CN(CCN(C)C1=NC=C(C(=O)NO)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCN(C)C1=NC=C(C(=O)NOC2CCCCO2)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NN4C(=O)OC(C)(C)C)=CN3C=CN=C23)C=C1.CN(CCN(C)C1=NC=C(C(=O)O)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CO Chemical compound CN(CCN(C)C1=NC=C(C(=O)NO)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCN(C)C1=NC=C(C(=O)NOC2CCCCO2)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NN4C(=O)OC(C)(C)C)=CN3C=CN=C23)C=C1.CN(CCN(C)C1=NC=C(C(=O)O)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CO YIDBICVNWSIVPT-UHFFFAOYSA-N 0.000 description 1
- KCJPFAAMMONFBX-UHFFFAOYSA-N CN(CCN(C)C1=NC=C(C(=O)NO)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCOCCC(=O)NO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CS(=O)(=O)N1CCN2C3=CC=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3OCC2C1.O=C(CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)OCO Chemical compound CN(CCN(C)C1=NC=C(C(=O)NO)C=N1)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CN(CCOCCC(=O)NO)C1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.CS(=O)(=O)N1CCN2C3=CC=C(NC4=NC(C5=CC6=C(C=C5)C=NC6)=CN5C=CN=C45)C=C3OCC2C1.O=C(CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)OCO KCJPFAAMMONFBX-UHFFFAOYSA-N 0.000 description 1
- IXHFNEAFAWRVCF-UHFFFAOYSA-N CNC(=O)C(C)C Chemical compound CNC(=O)C(C)C IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 description 1
- JUXBYXHPYWROJO-UHFFFAOYSA-N CNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.NOC1CCCCO1.O=C(NO)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 Chemical compound CNC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.NOC1CCCCO1.O=C(NO)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 JUXBYXHPYWROJO-UHFFFAOYSA-N 0.000 description 1
- GRXCPDMQTXDMRI-UHFFFAOYSA-N CO.O=C(CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2)COC1CCCCO1.O=C(CO)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O=CC(F)(F)F Chemical compound CO.O=C(CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2)COC1CCCCO1.O=C(CO)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O=CC(F)(F)F GRXCPDMQTXDMRI-UHFFFAOYSA-N 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- BWHAALZBIFMUAP-UHFFFAOYSA-N CON.CONC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.Cl.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 Chemical compound CON.CONC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.Cl.O=C(O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 BWHAALZBIFMUAP-UHFFFAOYSA-N 0.000 description 1
- PSXLPRASGLXGGK-UHFFFAOYSA-N CONC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(CO)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O=C(NO)C1=CC=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=C1.O=C(NO)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 Chemical compound CONC(=O)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1.O=C(CO)CCCCCCN1N=CC2=C1C=C(C1=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N1)C=C2.O=C(NO)C1=CC=C(NC(=O)C2=CC=CC(C3=CN4C=CN=C4C(NC4=CC=C(N5CCOCC5)C=C4)=N3)=C2)C=C1.O=C(NO)C1=CC=CC(C2=CN3C=CN=C3C(NC3=CC=C(N4CCOCC4)C=C3)=N2)=C1 PSXLPRASGLXGGK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MNXNKMLRCLQFIJ-UHFFFAOYSA-N O=C(CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)NO.O=C(CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)NOC1CCCCO1.O=C(O)CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1 Chemical compound O=C(CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)NO.O=C(CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1)NOC1CCCCO1.O=C(O)CCCC(=O)N1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1 MNXNKMLRCLQFIJ-UHFFFAOYSA-N 0.000 description 1
- GDXWIGAJVMQQAE-UHFFFAOYSA-N O=CNOC[V]CCCC1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.O=CNOC[V]CN1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1 Chemical compound O=CNOC[V]CCCC1=CC=C(NC2=NC(C3=CC4=C(C=C3)C=NC4)=CN3C=CN=C23)C=C1.O=CNOC[V]CN1CCN(C2=CC=C(NC3=NC(C4=CC5=C(C=C4)C=NC5)=CN4C=CN=C34)C=C2)CC1 GDXWIGAJVMQQAE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LFUPTQIEOBBAJE-VIFPVBQESA-N gtpl6338 Chemical compound C([C@@H](O1)C)NC(C2=3)=C1C=NC=3SC(C1=O)=C2N=CN1C1=CC=C(Cl)C=C1 LFUPTQIEOBBAJE-VIFPVBQESA-N 0.000 description 1
- KUCDOJMOTMEEOF-UHFFFAOYSA-N gtpl6345 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 KUCDOJMOTMEEOF-UHFFFAOYSA-N 0.000 description 1
- FODONWGPMXPGNC-UHFFFAOYSA-N gtpl6346 Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 FODONWGPMXPGNC-UHFFFAOYSA-N 0.000 description 1
- 125000004969 haloethyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention provides a novel class of heterocyclic compounds, the synthesis and use thereof, for example, as Syk (Spleen tyrosine kinase) inhibitors and/or Syk-HDAC (Histone deacetylase) dual inhibitors.
- Syk Single tyrosine kinase
- Syk-HDAC Histone deacetylase
- Syk is a non-receptor protein tyrosine kinase which is expressed in a variety of cells, especially in various hematopoietic cells. It is expressed in monocytes, macrophages, mast cells, basophils, eosinophils, neutrophils, immature T cells, CD4 effector T cells, B cells, natural killer cells, dendritic cells, platelets and red blood cells. In addition, expression of Syk is detected also in fibroblasts, osteoclasts, endothelial cells, and nerve cells. Syk also presents in various tissues such as epithelial cells of the lung, kidney, and cardiomyocytes. In 1991, Taniguchi et al.
- Syk contains 629 amino acid residues and consists of two tandem Src homodomains (N—SH2 and C—SH2) at the N-terminus and a kinase domain at the C-terminal. It shares a part of common structure with the protein kinase (ZAP-70), which is also a cytoplasmic protein kinase. Syk is activated by binding of the SH2 region to a tyrosine-dependent immunoreceptor tyrosinebased activation motifs (ITAM).
- ITAM tyrosine-dependent immunoreceptor tyrosinebased activation motifs
- Spleen tyrosine kinase is involved in the signal transduction process of many cells, and has attracted extensive attention as a cell signal transduction factor, especially an immune signal transduction factor.
- a cell signal transduction factor especially an immune signal transduction factor.
- Recent studies have shown that Syk plays a key role in inhibiting cell division and proliferation, and its overactivation can promote malignant cell proliferation and inhibit apoptosis, especially in B cells.
- Syk also affects the secretion of certain cytokines, and plays a key role in the production of cytokines in T cells and monocytes, bone resorption in osteoclasts, and phagocytosis of macrophages.
- Syk also affects the maturation and activation of immune cells and is closely related to allergic and antibody-mediated autoimmune diseases.
- Syk Since Syk is located in the upstream of the cellular signaling pathway, treatments targeting to Syk are more advantageous than drugs that inhibit single downstream pathway. Therefore, Syk has been used as a potential therapeutic target for a variety of diseases, such as chronic inflammatory diseases such as rheumatoid arthritis, allergic diseases (allergic rhinitis and asthma), multiple sclerosis, and immune diseases (rheumatoid arthritis), multiple tumors (breast, stomach, rectal, pancreatic, liver, B-cell lymphoma, chronic lymphocytic leukemia, non-Hawkings lymphoma, etc.), atherosclerosis (coronary heart disease and cerebral arterial thrombosis), gastrointestinal disorders, idiopathic thrombocytopenic purpura, Wiskott-Aldrich syndrome, and systemic lupus erythematosus.
- diseases such as chronic inflammatory diseases such as rheumatoid arthritis, allergic diseases (allergic rhinitis and asthma
- HDAC histone acetyltransferase
- the acetylation of histones reverses the acetylation of lysine residues of HAT and restores the positive charge of lysine residues, which facilitates the dissociation of DNA and histone octamers, and the relaxation of nucleosome structures, thus making various Transcription factors and co-transcription factors bind specifically to the DNA binding site and activate transcription of the gene. Due to the overexpression of HDAC in tumor cells, the deacetylation of histones is enhanced. By restoring the positive charge of histones and increasing the gravitation between DNA and histones, the relaxed nucleosomes become very tight, which is not conducive to specific Gene expression, including some tumor suppressor genes.
- HDAC inhibitors can regulate the expression and stability of apoptosis and differentiation-related proteins by increasing histone acetylation in specific regions of chromatin, induce tumor cell cycle arrest and apoptosis, promote tumor cell autophagy, and inhibit the formation of tumor angiogenesis, promotes the immunogenicity of tumor cells.
- HDAC inhibitors not only become a target for therapy for tumors, but also play a role in neurological diseases, inflammation, and promotion of autoimmunity.
- HDAC inhibitors can also effectively synergistically inhibit tumor growth when combined with other anti-tumor compounds.
- HDAC is responsible for removing acetyl groups on histones, which shows significant effects on gene expression, oncoprotein stability, cell migration, protein catabolism, and cell cycle regulation.
- Syk inhibitors or Syk-HDAC dual inhibitors would be able to used in a variety of cancers and other treatments for the disease.
- the object of the present invention is to provide a structurally novel Syk inhibitors or Syk-HDAC dual inhibitors, and the preparation method and application thereof.
- R 1 is aryl, heteroaryl or 6-membered monocyclic heterocyclyl (including saturated and unsaturated); aryl, heteroaryl or monocyclic heterocyclyl herein may be optionally and independently substituted by 1-3 substituents each independently selected from the group consisting of: halogen, C 1-4 alkyl, C 1-4 halogenated alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, NO 2 , OR 8 , SR 8 , NR 8 R 9 , C(O)R 8 , C(O)OR 8 , C(O)NR 8 R 9 , S(O) 2 R 8 or R 7 .
- R 2 , R 3 and R 4 are hydrogen
- U is selected from NR 5 ; where R 5 is hydrogen;
- B is a monocyclic aryl or bicyclic aryl group, or a monocyclic heteroaryl or bicyclic heteroaryl group, and at least one ring of the bicyclic aryl or bicyclic heteroaryl is aromatic, and the other ring is aromatic, saturated or partially saturated ring;
- Y is 3- to 12-membered monocyclic or polycyclic heterocyclic ring; wherein said heterocyclic ring contains 1-4 heteroatoms each independently selected from N, O and S;
- n 0 or 1
- each X is independently hydrogen, halogen, C 1-4 alkyl, C 3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, OR 8 , SR 8 , NR 8 R 9 , C(O)R 8 , C(O)OR 8 , C(O)NR 8 R 9 , or S(O) 2 R 8 ;
- R is hydrogen, —(CH 2 ) p —V—(CH 2 ) q C(O)NH(OH), —V 1 —(CH 2 ) p —V 2 —V—(CH 2 ) q C(O)NH(OH);
- R 7 is hydrogen, —(CH 2 ) p —V—(CH 2 ) q C(O)NH(OH), —V 1 —(CH 2 ) p —V 2 —V—(CH 2 ) q C(O)NH(OH), C(O)NH(OCH 3 ),
- G is NR 10 ;
- n 0, 1, 2, or 3;
- each R 6 is hydrogen, or two R 6 connecting to the same carbon atom form carbonyl group ( ⁇ O);
- R 8 and R 9 are each independently hydrogen, C 1-4 alkyl, C 1-4 halogenated alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl; or R 8 and R 9 together with the nitrogen atom to which they are attached form a 3- to 9-metacyclic ring comprising 1-2 N atom and 0, 1 or 2 heteroatoms selected from O or S;
- R 10 is C 2-8 alkyl, C 1-8 haloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 12-membered heterocyclyl (optionally comprising 1-2 heteroatoms selected from O, N, or S), aryl, heteroaryl, C(O)R 8 , C(O)OR 8 , C(O)NR 8 R 9 , S(O) 2 R 8 or (CH 2 ) p —V—(CH 2 ) q C(O)NH(OH), wherein R 8 is not hydrogen, and the R 8 in C(O)R 8 is not methyl;
- V is a divalent group, each of p and q is independently an integer from 0 to 10, and the V is selected from the group consisting of bond, O, S, NR 11 , OC(O), OC(O)O, NHC(O), NHC(O)NH, NHC(O)O, OC(O)NH, NHS(O) 2 , C(O), C(O)O, C(O)NH, S(O), S(O) 2 , S(O) 2 NH, or NHS(O) 2 NH, CH ⁇ CH, C ⁇ C, CR 12 R 13 , C 3-8 cycloalkyl, 3- to 12-member heterocyclyl, aryl or heteroaryl,
- V 1 and V 2 are divalent groups selected from the group consisting of bond, O, S, NR 11 , or C(O)NH, with the prerequisite that the group formed by V, V 1 , V 2 , p and q is chemically stable group;
- R 11 is hydrogen, C 1-4 alkyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, C(O)R 8 or S(O) 2 R 8 ;
- R 12 and R 13 are each independently hydrogen, halogen, C 1-4 alkyl, C 3-6 cycloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3- to 8-membered heterocyclic, OR 8 , SR 8 , NR 8 R 9 , CN, C(O)R 8 , C(O)OR 8 , C(O)NR 8 R 9 , OC(O)R 8 , NR 8 C(O)R 9 , or S(O) 2 R 8 , or R 12 and R 13 together with the carbon atoms to which they are attached form 3-8 membered cyclic structure containing 0, 1 or 2 heteroatoms selected from N, O, or S;
- R 7 is other than hydrogen, and the definitions of V, V 1 , V 2 , p and q in R 7 must ensure that the formed R 1 group is a stable chemical structure;
- each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally and independently substituted by 1-3 substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 halogenated alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3- to 8-heterocyclyl, aryl, heteroaryl, CN, NO 2 , OR 8 , SR 8 , NR 8 R 9 , C(O)R 8 , C(O)OR 8 , C(O)NR 8 R 9 or S(O) 2 R 8 ;
- the above aryl group is aryl group having 6 to 12 carbon atoms; and the heteroaryl group is 5- to 15-membered heteroaryl group.
- the R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- R 7 is as defined above.
- Y is a 4- to 12-membered monocyclic or polycyclic heterocycle having 1-4 heteroatoms each independently selected from N, O or S.
- Y is a 4- to 10-membered monocyclic or polycyclic heterocycle having 1-3 heteroatoms each independently selected from N, O or S.
- B is phenyl; Y is 6-membered monocyclic heterocyclic ring having 1-2 heteroatoms each independently being N, O or S, or Y is absent (m is 0).
- formula (II) is a structure selected from the group consisting of:
- D is N or CH
- k 1 and k 2 are each independently 0, 1, 2, or 3;
- X is hydrogen, halogen, C 1-4 alkyl, CN, or OR 5 ;
- R is hydrogen, —(CH 2 ) p —V—(CH 2 ) q C(O)NH(OH), —V 1 —(CH 2 ) p —V 2 —V—(CH 2 ) q C(O)NH(OH).
- formula (II) is a structure selected from the group consisting of:
- X is hydrogen, halogen, C 1-4 alkyl, CN, or OR 5 ; R is as described above.
- the formula (III) is a structure selected from the group consisting of:
- R 10 is C 2-8 alkyl, C 1-8 halogenated alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 6-membered heterocyclyl (optionally comprising 1-2 heteroatoms selected from O, N, S), aryl, heteroaryl, C(O)R 8 , C(O)OR 8 , C(O)NR 8 R 9 , S(O) 2 R 8 , wherein R 8 is selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl; wherein R 8 in C(O)R 8 is other than methyl; or R 8 and R 9 together with the nitrogen atom to which they are attached form a 3- to 9-membered ring comprising 1-2 N atom and 0, 1 or 2 heterocycl
- R is —(CH 2 ) p —V—(CH 2 ) q C(O)NH(OH) or —V 1 —(CH 2 ) p —V 2 —V—(CH 2 ) q C(O)NH(OH); wherein V is bond, O, NR 11 , CH ⁇ CH, aryl, heteroaryl, OC(O), NHC(O), C(O), S(O) 2 ; each R 11 is independently hydrogen or C 1-4 alkyl; p is 0, 1, 2, 3, or 4; q is 0, 1, 2, 3, 4, 5, 6, 7, or 8; V 1 and V 2 are each independently selected from NR 11 , O, S, or bond; with the proviso that the group formed by V, V 1 , and V 2 , p and q together is a stable chemical structure.
- each of R 1 , R 2 , R 3 , R 4 , U, A are the corresponding groups in compounds of the specific formula (I) prepared in the examples, respectively.
- formula (I) is selected from the group consisting of
- R 10 is C 2-8 alkyl, C 1-8 haloalkyl, C 3-8 cycloalkyl, unsubstituted or C 1-4 alkyl substituted 6-membered heterocyclyl (optionally containing 1-2 heteroatoms selected from O, or N), C(O)R 8 , or S(O) 2 R 8 ;
- R 8 is C 1-4 alkyl or C 1-4 haloalkyl; wherein the R 8 in C(O)R 8 is other than methyl.
- the R 10 is selected from the group consisting of ethyl, haloethyl, cyclopropyl, phenyl, 6-heterocyclyl unsubstituted or substituted by C 1-4 alkyl (optionally containing 1-2 heteroatoms selected from O or N), 5-6 membered heteroaryl unsubstituted or substituted by C 1-4 alkyl (optionally containing 1-2 hetero atoms selected from O or N), C(O)R 8 , S(O) 2 R 8 ; wherein R 8 is C 1-4 alkyl or C 1-4 halogenated alkyl; wherein the R 8 in C(O)R 8 is other than methyl.
- formula (I) is a structure selected from the group consisting of:
- V, V 1 , V 2 , p, and q are as defined above.
- the formula (I) compound is a structure selected from the group consisting of:
- R 7 is —(CH 2 ) p —V—(CH 2 ) q C(O)NH(OH) or —V 1 —(CH 2 ) p —V 2 —V—(CH 2 ) q C(O)NH(OH); wherein V is bond, O, NR 11 , CH ⁇ CH, aryl, heteroaryl, OC(O), NHC(O), C(O), S(O) 2 ; each R 11 is independently hydrogen or C 1-4 alkyl; p is 0, 1, 2, 3, or 4; q is 0, 1, 2, 3, 4, 5, 6, 7, or 8; V 1 and V 2 are each independently selected from NR 11 , O, S, or bond; with the proviso that the group formed by V, V 1 , and V 2 , p and q together is a stable chemical structure.
- the compound is selected from the following group:
- the formula (I) compound is used to treat diseases associated with Syk and/or HDAC kinase activity or expression level.
- a method of treating a disease associated with Syk and/or HDAC kinase activity or expression level comprising the steps: administering a therapeutically effective amount of a compound of formula (I) to a subject in need.
- a pharmaceutical composition which comprises: (i) therapeutically effective amount of formula (I) compound of the first aspect of the invention, or optical isomers, pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates thereof, and (ii) pharmaceutically acceptable carrier.
- the preparation method of compound of the first aspect of the present invention comprises the following steps:
- compound Ia reacts with A-NH 2 so as to provide compound Ib;
- each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
- alkyl refers to a straight (ie, unbranched) or branched saturated hydrocarbon group containing only carbon atoms, or a combination of straight and branched chains.
- the alkyl group has a carbon number limitation (e.g., C 1-10 ) it means that the alkyl group has 1 to 10 carbon atoms.
- C 1-8 alkyl refers to an alkyl group containing from 1 to 8 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, or the like. Group.
- alkenyl when used alone or as part of another substituent, refers to a straight or branched, carbon chain group having at least one carbon-carbon double bond. Alkenyl groups can be substituted or unsubstituted. When the alkenyl group has a carbon number limit (e.g., C 2-8 ), it means that the alkenyl group has 2-8 carbon atoms.
- C 2-8 alkenyl refers to alkenyl groups having 2-8 carbon atoms, including ethenyl, propenyl, 1,2-butenyl, 2,3-butenyl, butadienyl, or the like.
- alkynyl when used alone or as part of another substituent, refers to an aliphatic hydrocarbon group having at least one carbon-carbon triple bond.
- the alkynyl group can be straight or branched, or a combination thereof.
- the alkynyl group has a carbon number limitation (e.g., C 2-8 alkynyl group), it means that the alkynyl group has 2 to 8 carbon atoms.
- C 2-8 alkynyl refers to a straight or branched alkynyl group having 2-8 carbon atoms, including ethynyl, propynyl, isopropynyl, butynyl, isobutynyl, secondary Butynyl, tert-butynyl, or the like.
- cycloalkyl refers to a unit ring having a saturated or partially saturated ring, a bicyclic or polycyclic (fused ring, bridged or spiro) ring system.
- a certain cycloalkyl group has a carbon number limitation (e.g., C 3-10 ), it means that the cycloalkyl group has 3 to 10 carbon atoms.
- C 3-8 cycloalkyl refers to a saturated or partially saturated monocyclic or bicyclic alkyl group having from 3 to 8 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, or the like.
- Spirocycloalkyl refers to a bicyclic or polycyclic group that shares a carbon atom (called a spiro atom) between the monocyclic rings. These may contain one or more double bonds, but none of the rings have fully conjugated 1 L electrons system.
- “Fused cycloalkyl” means an all-carbon bicyclic or polycyclic group in which each ring of the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more double bond, but none of the rings have a fully conjugated R-electron system.
- “Bridged cycloalkyl” refers to an all-carbon polycyclic group in which two rings share two carbon atoms that are not directly bonded, which may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system.
- the atoms contained in the cycloalkyl group are all carbon atoms.
- Aryl means an all-carbon monocyclic or fused polycyclic (ie, a ring that shares a pair of adjacent carbon atoms) groups having a conjugated R-electron system, such as phenyl and naphthyl.
- the aryl ring may be fused to other cyclic groups (including saturated and unsaturated rings), but may not contain heteroatoms such as nitrogen, oxygen, or sulfur, while the point of attachment to the parent must be on the ring of carbon atoms of conjugated pi-electron system.
- the aryl group can be substituted or unsubstituted.
- the following are some examples of aryl groups, and the present invention is not limited to the aryl groups described below.
- Heteroaryl refers to a heteroaromatic group containing one to more heteroatoms.
- the heteroatoms referred to herein include oxygen, sulfur, and nitrogen.
- the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring wherein the ring to which the parent structure is attached is a heteroaryl ring.
- the heteroaryl group can be optionally substituted or unsubstituted.
- the following are some examples of heteroaryl groups, and the present invention is not limited to the following heteroaryl groups. Among them, the last three heteroaryl groups are tricyclic heteroaryl groups, which are the focus of the present invention.
- Heterocyclyl means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent wherein one or more of the ring atoms are selected from nitrogen, oxygen or sulfur and the remaining ring atoms are carbon.
- monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl.
- Polycyclic heterocyclic group refers to a heterocyclic group including a spiro ring, a fused ring, and a bridged ring.
- “Spirocyclic heterocyclyl” refers to a polycyclic heterocyclic group in which each ring of the system shares an atom (referred to as a spiro atom) with other rings in the system, wherein one or more of the ring atoms is selected from the group consisting of nitrogen and oxygen. Or sulfur, the remaining ring atoms are carbon.
- “Fused ring heterocyclyl” refers to a polycyclic heterocyclic group in which each ring of the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain one or more double bonds, but none One ring has a fully conjugated pi-electron system, and wherein one or more ring atoms are selected from nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon.
- “Bridged heterocyclyl” refers to a polycyclic heterocyclic group in which any two rings share two atoms which are not directly bonded, these may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system And wherein one or more of the ring atoms are selected from nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon. If a heterocyclic group has both a saturated ring and an aromatic ring (for example, the saturated ring and the aromatic ring are fused together), the point attached to the parent must be on the saturated ring. Note: When the point attached to the parent is on the aromatic ring, it is called a heteroaryl group and is not called a heterocyclic group. Some examples of the heterocyclic group are as follows, and the present invention is not limited to the following heterocyclic group.
- halogen when used alone or as part of another substituent, refers to F, Cl, Br, and I.
- substituted when with or without “optionally” means that one or more hydrogen atoms on a particular group are replaced by a particular substituent.
- Particular substituents are the substituents described above in the corresponding paragraphs, or the substituents which appear in the examples.
- an optionally substituted group may have a substituent selected from a particular group at any substitutable position of the group, and the substituents may be the same or different at each position.
- a cyclic substituent, such as a heterocyclic group may be attached to another ring, such as a cycloalkyl group, to form a spirobicyclic ring system, i.e., the two rings have a common carbon atom.
- substituents contemplated by the present invention are those that are stable or chemically achievable.
- the substituents are, for example but not limited to, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 12-membered heterocyclic, aryl, Heteroaryl, halogen, hydroxy, carboxy (—COOH), C 1-8 aldehyde, C 2-10 acyl, C 2-10 ester, amino.
- a pharmaceutically acceptable salt of a compound of the invention refers to a salt that is suitable for contact with the tissue of a subject (eg, a human) without causing unpleasant side effects.
- a pharmaceutically acceptable salt of a compound of the invention includes a salt (eg, a potassium salt, a sodium salt, a magnesium salt, a calcium salt) of a compound of the invention having an acidic group or is basic A salt of a compound of the invention (e.g., a sulfate, a hydrochloride, a phosphate, a nitrate, a carbonate).
- the compound of the formula (I) of the present invention can be prepared by the following method:
- the groups are defined as above.
- the reagents and conditions for each step may be selected from those conventional in the art for carrying out such preparation methods. After the structure of the compound of the present invention is disclosed, the above selection may be carried out by those skilled in the art based on the knowledge in the art.
- the compound of the formula I of the present invention can be obtained by the following method, however, the conditions of the method, such as the reactant, the solvent, the base, the amount of the compound used, the reaction temperature, the reaction time, are not limited to the explanation below.
- the compounds of the invention may also be easily prepared by optionally combine various synthetic methods described in this specification or known in the art, such a combination can be easily performed by one of ordinary skill in the art of the present invention.
- each reaction is usually carried out in an inert solvent, and the reaction temperature is usually ⁇ 20 to 150° C. (preferably 0 to 120° C.).
- the reaction time of each step is usually 0.5 to 48 h, preferably 2 to 12 h.
- the compound of the present invention has excellent Syk kinases inhibitory activity and/or Syk-HDAC dual inhibitory activity
- the compound of the present invention, the related deuterated compounds thereof, the possible isomers thereof (enantiomers or diastereoisomers thereof), and various crystal forms thereof, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions comprising compounds containing the present invention can be used to treat, prevent, and alleviate diseases associated with Syk or HDAC activity or expression levels.
- the compound of the present invention can be used to treat diseases selected from the group consisting (but not limited to) lymphoma, lymphocytic leukemia, cutaneous T-cell lymphoma, rectal cancer, breast cancer, stomach cancer, pancreatic cancer, liver cancer, lung cancer, head and neck cancer, kidney cancer, colon cancer, ovarian cancer, prostate cancer, multiple sclerosis, immunity diseases (rheumatoid arthritis and nephritis), allergic diseases (allergic rhinitis and asthma), atherosclerosis (coronary heart disease and ischemic stroke), gastrointestinal disorders, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, Alzheimer's disease, stroke and coronary artery disease, Wiskott-Aldrich syndrome, myelofibrosis, AIDS, etc.
- diseases selected from the group consisting (but not limited to) lymphoma, lymphocytic leukemia, cutaneous T-cell lymphoma, rectal cancer
- compositions of the present invention comprise a safe or effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
- safe and effective amount it is meant that the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
- the pharmaceutical compositions contain from 1 to 2000 mg of the compound of the invention per agent, more preferably from 5 to 200 mg of the compound of the invention per agent.
- the “one dose” is a capsule or tablet.
- “Pharmaceutically acceptable carrier” means: one or more compatible solid or liquid fillers or gel materials which are suitable for human use and which must be of sufficient purity and of sufficiently low toxicity.
- “compatibility” it is meant herein that the components of the composition are capable of intermingling with the compounds of the invention and with each other without significantly reducing the efficacy of the compound.
- Examples of pharmaceutically acceptable carriers are cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid), magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as Tween®), run Wet agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
- cellulose and its derivatives such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
- gelatin such as talc
- solid lubricants such as stearic acid
- magnesium stearate magnesium
- the mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with: (a) a filler or compatibilizer, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) a binder such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) a humectant such as glycerin; (d) a disintegrant, for example, Agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent such as paraffin; (f) an absorption accelerator, for example, a quaternary amine compound; (g) Wetting agents such as cetyl alcohol
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other materials known in the art. They may contain opacifying agents and the release of the active compound or compound in such compositions may be released in a portion of the digestive tract in a delayed manner. Examples of embedding components that can be employed are polymeric and waxy materials. If necessary, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs.
- the liquid dosage form may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or a mixture of these substances.
- inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide
- compositions may contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
- the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these and the like.
- suspending agents for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these and the like.
- compositions for parenteral injection may comprise a physiologically acceptable sterile aqueous or nonaqueous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion.
- Suitable aqueous and nonaqueous vehicles, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
- Dosage forms for the compounds of the invention for topical administration include ointments, powders, patches, propellants and inhalants.
- the active ingredient is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or, if necessary, propellants.
- the compounds of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
- a safe and effective amount of a compound of the invention is administered to a mammal (e.g., a human) in need of treatment wherein the dosage is a pharmaceutically effective dosage, for a 60 kg body weight.
- the dose to be administered is usually from 1 to 2000 mg, preferably from 5 to 500 mg, Of course, specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
- Syk kinase inhibitor and/or Syk-HDAC dual inhibitor and the preparation and use thereof.
- the inhibitor can inhibit the activities of Syk and HDAC kinases at very low concentrations.
- Trifluoroacetic acid salt of compound 1Ra 150 mg, 0.43 mmol
- 1-ethoxy-1-trimethylsiloxycyclopropane (234 mg, 1.34 mmol) were dissolved in methanol (6 ml), and sodium cyanoborohydride (84 mg, 1.34 mmol) was added under stirring.
- the reaction system was heated to 65° C. and stirred for 16 hours, TLC monitoring shown that the reaction was completed.
- the reaction system was cooled to room temperature, then poured into saturated sodium carbonate solution (10 ml), and extracted with ethyl acetate (15 ml ⁇ 3).
- the combined organic layer was washed with brine (15 ml) and dried over anhydrous sodium sulfate and filtered.
- 6-Bromoindazole 0.5 g, 2.54 mmol
- bis(pinacolato)diboron 0.7 g, 2.79 mmol
- potassium acetate 0.7 g, 7.62 mmol
- dimethyl sulfoxide 15 mL
- Pd(dppf)Cl 2 .DCM 310 mg, 0.38 mmol
- TLC monitored that the raw material disappeared, and product was formed.
- the reaction was cooled to room temperature, and ethyl acetate (25 ml) and water (25 ml) were added to dilute the reaction solution and filtered.
- Compound 12b was prepared by compound 12a according to the synthesis of compound 1b.
- the synthesis method of 12 from 11e and 12b by a multi-step reaction can refer to the synthesis of compound 10.
- Compound 17 was prepared from compound 13a by a multi-step reaction. The specific experimental procedure was according to the synthesis of the above compound 10-13.
- Compound 18 was prepared by a multi-step reaction from compound 18a and compound 10c. The specific experimental procedure was according to the synthesis of the above compound 10-13.
- 22a (4.0 g, 19.8 mmol) was dissolved in N,N-dimethylacetamide (30.5 mL), then 22b (2.2 g, 29.7 mmol), potassium carbonate (8.2 g, 59.4 mmol), potassium iodide (329 mg, 1.9 mmol), cuprous iodide (377 mg, 1.9 mmol), and L-valine (228 mg, 1.9 mmol) were added successively. The reaction system was replaced with nitrogen for three times, and heated to 120° C. and stirred overnight.
- 22c 500 mg, 2.5 mmol
- 22d 5.0 ml
- potassium hydroxide 50 mg, 0.7 mmol
- the reaction system was blown with nitrogen, and heated to 120° C. and stirred overnight.
- SYK protein kinase activity was carried out by using the Caliper mobility shift assay.
- the compound was dissolved with DMSO and diluted with kinase buffer (20 mM HEPES pH 7.5, 0.01% Triton X-100, 5 mM MgCl 2 , 1 mM MnCl 2 , 2 mM DTT), and 5 ⁇ l of 5 times the final concentration of the compounds (10% DMSO) were added to 384 well plate.
- 10 ⁇ l of 2.5 fold enzyme (with SYK) solution was added and incubated at room temperature for 10 minutes, then 10 ⁇ l of 2.5 fold substrate (Peptide FAM-P22) and ATP) solution was added.
- HDAC activity was measured by the Synergy MX Multi-Function Microplate Reader.
- the max refers to the fluorescence intensity of the DMSO control
- min refers to the fluorescence intensity of the enzyme-free control.
- the curve was drawn with the compound concentration and inhibition rate as the horizontal and vertical coordinates, and the curve was fitted with the GraphPad Prism V5.0 Software, and IC 50 was calculated.
- HDAC1 (IC 50 , nM)
- HDAC6 (IC 50 , nM) 6 ⁇ 1000 ⁇ 50 7 ⁇ 30 ⁇ 30 10 ⁇ 2000 12 ⁇ 200 13 ⁇ 200 14 ⁇ 20 17 ⁇ 50 18 ⁇ 100 19 ⁇ 500 20 ⁇ 20 21 ⁇ 100 22 ⁇ 500 23 ⁇ 30
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
A heterocyclic compound as a Syk inhibitor and/or a Syk-HDAC dual inhibitor, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, and solvates thereof are provided. Specifically, a compound of formula (I) is provided, which has dual inhibitory activity for Syk and/or Syk-HDAC.
Description
- This application is a divisional of U.S. application Ser. No. 16/468,902 filed Jun. 12, 2019, which is a Section 371 of International Application No. PCT/CN2017/115755, filed Dec. 12, 2017, which was published in the Chinese language on Jun. 21, 2018, under International Publication No. WO 2018/108083 A1, which claims priority under 35 U.S.C. § 119(b) to Chinese Application No. 201611141394.8, filed Dec. 12, 2016, the disclosures of which are incorporated herein by reference in their entirety.
- The present invention provides a novel class of heterocyclic compounds, the synthesis and use thereof, for example, as Syk (Spleen tyrosine kinase) inhibitors and/or Syk-HDAC (Histone deacetylase) dual inhibitors.
- Syk is a non-receptor protein tyrosine kinase which is expressed in a variety of cells, especially in various hematopoietic cells. It is expressed in monocytes, macrophages, mast cells, basophils, eosinophils, neutrophils, immature T cells, CD4 effector T cells, B cells, natural killer cells, dendritic cells, platelets and red blood cells. In addition, expression of Syk is detected also in fibroblasts, osteoclasts, endothelial cells, and nerve cells. Syk also presents in various tissues such as epithelial cells of the lung, kidney, and cardiomyocytes. In 1991, Taniguchi et al. isolated a protein kinase with a molecular weight of 72 kDa from the cDNA of pig spleen, and named it Syk. Syk contains 629 amino acid residues and consists of two tandem Src homodomains (N—SH2 and C—SH2) at the N-terminus and a kinase domain at the C-terminal. It shares a part of common structure with the protein kinase (ZAP-70), which is also a cytoplasmic protein kinase. Syk is activated by binding of the SH2 region to a tyrosine-dependent immunoreceptor tyrosinebased activation motifs (ITAM).
- Spleen tyrosine kinase is involved in the signal transduction process of many cells, and has attracted extensive attention as a cell signal transduction factor, especially an immune signal transduction factor. Recent studies have shown that Syk plays a key role in inhibiting cell division and proliferation, and its overactivation can promote malignant cell proliferation and inhibit apoptosis, especially in B cells. Syk also affects the secretion of certain cytokines, and plays a key role in the production of cytokines in T cells and monocytes, bone resorption in osteoclasts, and phagocytosis of macrophages. Syk also affects the maturation and activation of immune cells and is closely related to allergic and antibody-mediated autoimmune diseases. Since Syk is located in the upstream of the cellular signaling pathway, treatments targeting to Syk are more advantageous than drugs that inhibit single downstream pathway. Therefore, Syk has been used as a potential therapeutic target for a variety of diseases, such as chronic inflammatory diseases such as rheumatoid arthritis, allergic diseases (allergic rhinitis and asthma), multiple sclerosis, and immune diseases (rheumatoid arthritis), multiple tumors (breast, stomach, rectal, pancreatic, liver, B-cell lymphoma, chronic lymphocytic leukemia, non-Hawkings lymphoma, etc.), atherosclerosis (coronary heart disease and cerebral arterial thrombosis), gastrointestinal disorders, idiopathic thrombocytopenic purpura, Wiskott-Aldrich syndrome, and systemic lupus erythematosus.
- HDAC is a class of proteases that play an important role in the structural modification of chromosomes and the regulation of gene expression. HDAC deacetylates the lysine side chain at the amino terminus of histones, and histone acetylation is in a dynamic equilibrium with histone deacetylation, which is regulated by histone acetyltransferase (HAT) and histone deacetylase. The acetylation of histones reverses the acetylation of lysine residues of HAT and restores the positive charge of lysine residues, which facilitates the dissociation of DNA and histone octamers, and the relaxation of nucleosome structures, thus making various Transcription factors and co-transcription factors bind specifically to the DNA binding site and activate transcription of the gene. Due to the overexpression of HDAC in tumor cells, the deacetylation of histones is enhanced. By restoring the positive charge of histones and increasing the gravitation between DNA and histones, the relaxed nucleosomes become very tight, which is not conducive to specific Gene expression, including some tumor suppressor genes.
- HDAC inhibitors can regulate the expression and stability of apoptosis and differentiation-related proteins by increasing histone acetylation in specific regions of chromatin, induce tumor cell cycle arrest and apoptosis, promote tumor cell autophagy, and inhibit the formation of tumor angiogenesis, promotes the immunogenicity of tumor cells. HDAC inhibitors not only become a target for therapy for tumors, but also play a role in neurological diseases, inflammation, and promotion of autoimmunity.
- Preclinical and clinical studies have shown that HDAC inhibitors can also effectively synergistically inhibit tumor growth when combined with other anti-tumor compounds. HDAC is responsible for removing acetyl groups on histones, which shows significant effects on gene expression, oncoprotein stability, cell migration, protein catabolism, and cell cycle regulation.
- Study of Hagiwara, K. et al. on 2015 published in Apoptosis confirmed that the combination of the Syk inhibitor R406 and the HDAC inhibitor vorinostat has synergistically potentiating effects on killing mantle cell lymphoma cells.
- In summary, Syk inhibitors or Syk-HDAC dual inhibitors would be able to used in a variety of cancers and other treatments for the disease.
- The object of the present invention is to provide a structurally novel Syk inhibitors or Syk-HDAC dual inhibitors, and the preparation method and application thereof.
- In the first aspect of the present invention, a compound of formula (I), or the pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates thereof is provided:
- wherein in the formula (I),
- R1 is aryl, heteroaryl or 6-membered monocyclic heterocyclyl (including saturated and unsaturated); aryl, heteroaryl or monocyclic heterocyclyl herein may be optionally and independently substituted by 1-3 substituents each independently selected from the group consisting of: halogen, C1-4 alkyl, C1-4 halogenated alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, NO2, OR8, SR8, NR8R9, C(O)R8, C(O)OR8, C(O)NR8R9, S(O)2R8 or R7.
- R2, R3 and R4 are hydrogen;
- U is selected from NR5; where R5 is hydrogen;
- A selected from the group consisting of formula (II) or formula (III):
- wherein:
-
- “*” indicates a chiral center;
- B is a monocyclic aryl or bicyclic aryl group, or a monocyclic heteroaryl or bicyclic heteroaryl group, and at least one ring of the bicyclic aryl or bicyclic heteroaryl is aromatic, and the other ring is aromatic, saturated or partially saturated ring;
- Y is 3- to 12-membered monocyclic or polycyclic heterocyclic ring; wherein said heterocyclic ring contains 1-4 heteroatoms each independently selected from N, O and S;
- m is 0 or 1;
- each X is independently hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, OR8, SR8, NR8R9, C(O)R8, C(O)OR8, C(O)NR8R9, or S(O)2R8;
- R is hydrogen, —(CH2)p—V—(CH2)qC(O)NH(OH), —V1—(CH2)p—V2—V—(CH2)qC(O)NH(OH);
- R7 is hydrogen, —(CH2)p—V—(CH2)qC(O)NH(OH), —V1—(CH2)p—V2—V—(CH2)qC(O)NH(OH), C(O)NH(OCH3),
- J is O;
- G is NR10;
- n is 0, 1, 2, or 3;
- each R6 is hydrogen, or two R6 connecting to the same carbon atom form carbonyl group (═O);
- R8 and R9 are each independently hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl; or R8 and R9 together with the nitrogen atom to which they are attached form a 3- to 9-metacyclic ring comprising 1-2 N atom and 0, 1 or 2 heteroatoms selected from O or S;
- R10 is C2-8 alkyl, C1-8 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 3- to 12-membered heterocyclyl (optionally comprising 1-2 heteroatoms selected from O, N, or S), aryl, heteroaryl, C(O)R8, C(O)OR8, C(O)NR8R9, S(O)2R8 or (CH2)p—V—(CH2)qC(O)NH(OH), wherein R8 is not hydrogen, and the R8 in C(O)R8 is not methyl;
- V is a divalent group, each of p and q is independently an integer from 0 to 10, and the V is selected from the group consisting of bond, O, S, NR11, OC(O), OC(O)O, NHC(O), NHC(O)NH, NHC(O)O, OC(O)NH, NHS(O)2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)2NH, or NHS(O)2NH, CH═CH, C≡C, CR12R13, C3-8 cycloalkyl, 3- to 12-member heterocyclyl, aryl or heteroaryl,
- with the prerequisite that V, p and q together form a chemically stable group;
- V1 and V2 are divalent groups selected from the group consisting of bond, O, S, NR11, or C(O)NH, with the prerequisite that the group formed by V, V1, V2, p and q is chemically stable group;
- R11 is hydrogen, C1-4 alkyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, C(O)R8 or S(O)2R8;
- R12 and R13 are each independently hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, 3- to 8-membered heterocyclic, OR8, SR8, NR8R9, CN, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8, NR8C(O)R9, or S(O)2R8, or R12 and R13 together with the carbon atoms to which they are attached form 3-8 membered cyclic structure containing 0, 1 or 2 heteroatoms selected from N, O, or S;
- with the prerequisite that when the formula (II) is
- then the R1 is
- herein R7 is other than hydrogen, and the definitions of V, V1, V2, p and q in R7 must ensure that the formed R1 group is a stable chemical structure;
- another proviso is that when R1 does not comprise structural unit
- than A is of formula (IIa) or formula (IIIa), wherein R comprises structural unit
- wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally and independently substituted by 1-3 substituents each independently selected from the group consisting of halogen, C1-4 alkyl, C1-4 halogenated alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-heterocyclyl, aryl, heteroaryl, CN, NO2, OR8, SR8, NR8R9, C(O)R8, C(O)OR8, C(O)NR8R9 or S(O)2R8;
- unless otherwise specified, the above aryl group is aryl group having 6 to 12 carbon atoms; and the heteroaryl group is 5- to 15-membered heteroaryl group.
- In another preferred embodiment, the R1 is
- wherein the R7 is as defined above.
- In another preferred embodiment, Y is a 4- to 12-membered monocyclic or polycyclic heterocycle having 1-4 heteroatoms each independently selected from N, O or S.
- In another preferred embodiment, Y is a 4- to 10-membered monocyclic or polycyclic heterocycle having 1-3 heteroatoms each independently selected from N, O or S.
- In another preferred embodiment, B is phenyl; Y is 6-membered monocyclic heterocyclic ring having 1-2 heteroatoms each independently being N, O or S, or Y is absent (m is 0).
- In another preferred embodiment, formula (II) is a structure selected from the group consisting of:
- where D is N or CH;
- k1 and k2 are each independently 0, 1, 2, or 3;
- X is hydrogen, halogen, C1-4 alkyl, CN, or OR5;
- R is hydrogen, —(CH2)p—V—(CH2)qC(O)NH(OH), —V1—(CH2)p—V2—V—(CH2)qC(O)NH(OH).
- In another preferred embodiment, the formula (II) is a structure selected from the group consisting of:
- wherein X is hydrogen, halogen, C1-4 alkyl, CN, or OR5; R is as described above.
- In another preferred embodiment, the formula (III) is a structure selected from the group consisting of:
- wherein R10 is C2-8 alkyl, C1-8 halogenated alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 6-membered heterocyclyl (optionally comprising 1-2 heteroatoms selected from O, N, S), aryl, heteroaryl, C(O)R8, C(O)OR8, C(O)NR8R9, S(O)2R8, wherein R8 is selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl; wherein R8 in C(O)R8 is other than methyl; or R8 and R9 together with the nitrogen atom to which they are attached form a 3- to 9-membered ring comprising 1-2 N atom and 0, 1 or 2 hetero atoms selected from O or S.
- In another preferred embodiment, R is —(CH2)p—V—(CH2)qC(O)NH(OH) or —V1—(CH2)p—V2—V—(CH2)qC(O)NH(OH); wherein V is bond, O, NR11, CH═CH, aryl, heteroaryl, OC(O), NHC(O), C(O), S(O)2; each R11 is independently hydrogen or C1-4 alkyl; p is 0, 1, 2, 3, or 4; q is 0, 1, 2, 3, 4, 5, 6, 7, or 8; V1 and V2 are each independently selected from NR11, O, S, or bond; with the proviso that the group formed by V, V1, and V2, p and q together is a stable chemical structure.
- In another preferred embodiment, each of R1, R2, R3, R4, U, A are the corresponding groups in compounds of the specific formula (I) prepared in the examples, respectively.
- In another preferred embodiment, the formula (I) is selected from the group consisting of
- wherein R10 is C2-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, unsubstituted or C1-4 alkyl substituted 6-membered heterocyclyl (optionally containing 1-2 heteroatoms selected from O, or N), C(O)R8, or S(O)2R8; R8 is C1-4 alkyl or C1-4 haloalkyl; wherein the R8 in C(O)R8 is other than methyl.
- In another preferred embodiment, the R10 is selected from the group consisting of ethyl, haloethyl, cyclopropyl, phenyl, 6-heterocyclyl unsubstituted or substituted by C1-4 alkyl (optionally containing 1-2 heteroatoms selected from O or N), 5-6 membered heteroaryl unsubstituted or substituted by C1-4 alkyl (optionally containing 1-2 hetero atoms selected from O or N), C(O)R8, S(O)2R8; wherein R8 is C1-4 alkyl or C1-4 halogenated alkyl; wherein the R8 in C(O)R8 is other than methyl.
- In another preferred embodiment, formula (I) is a structure selected from the group consisting of:
- wherein V, V1, V2, p, and q are as defined above.
- In another preferred embodiment, the formula (I) compound is a structure selected from the group consisting of:
- wherein R7 is —(CH2)p—V—(CH2)qC(O)NH(OH) or —V1—(CH2)p—V2—V—(CH2)qC(O)NH(OH); wherein V is bond, O, NR11, CH═CH, aryl, heteroaryl, OC(O), NHC(O), C(O), S(O)2; each R11 is independently hydrogen or C1-4 alkyl; p is 0, 1, 2, 3, or 4; q is 0, 1, 2, 3, 4, 5, 6, 7, or 8; V1 and V2 are each independently selected from NR11, O, S, or bond; with the proviso that the group formed by V, V1, and V2, p and q together is a stable chemical structure.
- In another preferred embodiment, the compound is selected from the following group:
- In the second aspect of the present invention, a use of compound of formula (I) according to the first aspect of the invention, or optical isomers, pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates thereof is provided, wherein in:
- (a) preparation of medicine for treating diseases associated with Syk and/or HDAC kinase activity or expression level;
- (b) preparation of Syk and/or HDAC kinase targeting inhibitor; and/or
- (c) in vitro non-therapeutic inhibition of Syk and/or HDAC kinase activity;
- In another preferred embodiment, the formula (I) compound is used to treat diseases associated with Syk and/or HDAC kinase activity or expression level.
- In another preferred embodiment, a method of treating a disease associated with Syk and/or HDAC kinase activity or expression level is provided, comprising the steps: administering a therapeutically effective amount of a compound of formula (I) to a subject in need.
- In the third aspect of the present invention, a pharmaceutical composition is provided, which comprises: (i) therapeutically effective amount of formula (I) compound of the first aspect of the invention, or optical isomers, pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates thereof, and (ii) pharmaceutically acceptable carrier.
- In the fourth aspect of the present invention, the preparation method of compound of the first aspect of the present invention is provided, which comprises the following steps:
- (1) In an inert solvent, compound Ia reacts with A-NH2 so as to provide compound Ib;
- (2) In an inert solvent, compound Ib reacts with compound R1B(OH)2 to obtain formula I compound;
- (3) The C(O)NH(OH) group in A or R1 in the compound of formula (I) is prepared from the corresponding carboxylic ester. The carboxylic ester Ic or Id is hydrolyzed, and the resulting acid is further reacted with a tetrahydropyran protected hydroxylamine, and finally the tetrahydropyran protecting group is deprotected to give a hydroxyamide 1e or 1f. The general scheme is as follows:
- In the above formulas, the groups are defined as above.
- It should be understood that, in the present invention, each of the technical features specifically described above and below (such as those in the Examples) can be combined with each other, thereby constituting new or preferred technical solutions which need not be specified again herein.
- After long-term and intensive research, the inventors have unexpectedly discovered a class of heterocyclic compounds having Syk (spleen tyrosine kinase) inhibitory activity or Syk-HDAC dual inhibitory activity, thus being able to used in the preparation of pharmaceutical compositions for treating diseases associated with the activity or expression level of Syk and or HDAC. The present invention is completed on this basis.
- Unless otherwise stated, “or” as used herein has the same meaning as “and/or” (refers to “or” and “and”).
- Unless otherwise specified, among all compounds of the present invention, each chiral carbon atom (chiral center) may optionally be in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
- As used herein, the term “alkyl”, alone or as part of another substituent, refers to a straight (ie, unbranched) or branched saturated hydrocarbon group containing only carbon atoms, or a combination of straight and branched chains. When the alkyl group has a carbon number limitation (e.g., C1-10), it means that the alkyl group has 1 to 10 carbon atoms. For example, C1-8 alkyl refers to an alkyl group containing from 1 to 8 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, or the like. Group.
- As used herein, the term “alkenyl”, when used alone or as part of another substituent, refers to a straight or branched, carbon chain group having at least one carbon-carbon double bond. Alkenyl groups can be substituted or unsubstituted. When the alkenyl group has a carbon number limit (e.g., C2-8), it means that the alkenyl group has 2-8 carbon atoms. For example, C2-8 alkenyl refers to alkenyl groups having 2-8 carbon atoms, including ethenyl, propenyl, 1,2-butenyl, 2,3-butenyl, butadienyl, or the like.
- As used herein, the term “alkynyl”, when used alone or as part of another substituent, refers to an aliphatic hydrocarbon group having at least one carbon-carbon triple bond. The alkynyl group can be straight or branched, or a combination thereof. When the alkynyl group has a carbon number limitation (e.g., C2-8 alkynyl group), it means that the alkynyl group has 2 to 8 carbon atoms. For example, the term “C2-8 alkynyl” refers to a straight or branched alkynyl group having 2-8 carbon atoms, including ethynyl, propynyl, isopropynyl, butynyl, isobutynyl, secondary Butynyl, tert-butynyl, or the like.
- As used herein, when used alone or as part of another substituent, the term “cycloalkyl” refers to a unit ring having a saturated or partially saturated ring, a bicyclic or polycyclic (fused ring, bridged or spiro) ring system. When a certain cycloalkyl group has a carbon number limitation (e.g., C3-10), it means that the cycloalkyl group has 3 to 10 carbon atoms. In some preferred embodiments, the term “C3-8 cycloalkyl” refers to a saturated or partially saturated monocyclic or bicyclic alkyl group having from 3 to 8 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, or the like. “Spirocycloalkyl” refers to a bicyclic or polycyclic group that shares a carbon atom (called a spiro atom) between the monocyclic rings. These may contain one or more double bonds, but none of the rings have fully conjugated 1 L electrons system. “Fused cycloalkyl” means an all-carbon bicyclic or polycyclic group in which each ring of the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more double bond, but none of the rings have a fully conjugated R-electron system. “Bridged cycloalkyl” refers to an all-carbon polycyclic group in which two rings share two carbon atoms that are not directly bonded, which may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. The atoms contained in the cycloalkyl group are all carbon atoms. Some examples of cycloalkyl groups are as follows, and the present invention is not limited to the following cycloalkyl groups.
- Unless otherwise stated, the following terms used in the specification and claims have the following meanings. “Aryl” means an all-carbon monocyclic or fused polycyclic (ie, a ring that shares a pair of adjacent carbon atoms) groups having a conjugated R-electron system, such as phenyl and naphthyl. The aryl ring may be fused to other cyclic groups (including saturated and unsaturated rings), but may not contain heteroatoms such as nitrogen, oxygen, or sulfur, while the point of attachment to the parent must be on the ring of carbon atoms of conjugated pi-electron system. The aryl group can be substituted or unsubstituted. The following are some examples of aryl groups, and the present invention is not limited to the aryl groups described below.
- “Heteroaryl” refers to a heteroaromatic group containing one to more heteroatoms. The heteroatoms referred to herein include oxygen, sulfur, and nitrogen. For example, furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring wherein the ring to which the parent structure is attached is a heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted. The following are some examples of heteroaryl groups, and the present invention is not limited to the following heteroaryl groups. Among them, the last three heteroaryl groups are tricyclic heteroaryl groups, which are the focus of the present invention.
- “Heterocyclyl” means a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent wherein one or more of the ring atoms are selected from nitrogen, oxygen or sulfur and the remaining ring atoms are carbon. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl. Polycyclic heterocyclic group refers to a heterocyclic group including a spiro ring, a fused ring, and a bridged ring. “Spirocyclic heterocyclyl” refers to a polycyclic heterocyclic group in which each ring of the system shares an atom (referred to as a spiro atom) with other rings in the system, wherein one or more of the ring atoms is selected from the group consisting of nitrogen and oxygen. Or sulfur, the remaining ring atoms are carbon. “Fused ring heterocyclyl” refers to a polycyclic heterocyclic group in which each ring of the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain one or more double bonds, but none One ring has a fully conjugated pi-electron system, and wherein one or more ring atoms are selected from nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon. “Bridged heterocyclyl” refers to a polycyclic heterocyclic group in which any two rings share two atoms which are not directly bonded, these may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system And wherein one or more of the ring atoms are selected from nitrogen, oxygen or sulfur, and the remaining ring atoms are carbon. If a heterocyclic group has both a saturated ring and an aromatic ring (for example, the saturated ring and the aromatic ring are fused together), the point attached to the parent must be on the saturated ring. Note: When the point attached to the parent is on the aromatic ring, it is called a heteroaryl group and is not called a heterocyclic group. Some examples of the heterocyclic group are as follows, and the present invention is not limited to the following heterocyclic group.
- As used herein, the term “halogen”, when used alone or as part of another substituent, refers to F, Cl, Br, and I.
- As used herein, the term “substituted” (when with or without “optionally”) means that one or more hydrogen atoms on a particular group are replaced by a particular substituent. Particular substituents are the substituents described above in the corresponding paragraphs, or the substituents which appear in the examples. Unless otherwise stated, an optionally substituted group may have a substituent selected from a particular group at any substitutable position of the group, and the substituents may be the same or different at each position. A cyclic substituent, such as a heterocyclic group, may be attached to another ring, such as a cycloalkyl group, to form a spirobicyclic ring system, i.e., the two rings have a common carbon atom. Those skilled in the art will appreciate that the combinations of substituents contemplated by the present invention are those that are stable or chemically achievable. The substituents are, for example but not limited to, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 3- to 12-membered heterocyclic, aryl, Heteroaryl, halogen, hydroxy, carboxy (—COOH), C1-8 aldehyde, C2-10 acyl, C2-10 ester, amino.
- For convenience and in accordance with conventional understanding, the term “optionally substituted” or “optionally substituted” applies only to sites which are capable of being substituted by a substituent, and does not include those which are not chemically achievable.
- As used herein, unless otherwise specified, the term “pharmaceutically acceptable salt” refers to a salt that is suitable for contact with the tissue of a subject (eg, a human) without causing unpleasant side effects. In some embodiments, a pharmaceutically acceptable salt of a compound of the invention includes a salt (eg, a potassium salt, a sodium salt, a magnesium salt, a calcium salt) of a compound of the invention having an acidic group or is basic A salt of a compound of the invention (e.g., a sulfate, a hydrochloride, a phosphate, a nitrate, a carbonate).
- General Synthetic Method of Compounds
- The compound of the formula (I) of the present invention can be prepared by the following method:
- (1) in an inert solvent, reacting formula Ia compound with A-NH2 so as to provide compound Ib;
- (2) In an inert solvent, reacting compound Ib and R1B(OH)2 compound to obtain formula I compound;
- In the above formulas, the groups are defined as above. The reagents and conditions for each step may be selected from those conventional in the art for carrying out such preparation methods. After the structure of the compound of the present invention is disclosed, the above selection may be carried out by those skilled in the art based on the knowledge in the art.
- More specifically, the compound of the formula I of the present invention can be obtained by the following method, however, the conditions of the method, such as the reactant, the solvent, the base, the amount of the compound used, the reaction temperature, the reaction time, are not limited to the explanation below. The compounds of the invention may also be easily prepared by optionally combine various synthetic methods described in this specification or known in the art, such a combination can be easily performed by one of ordinary skill in the art of the present invention.
- In the production method of the present invention, each reaction is usually carried out in an inert solvent, and the reaction temperature is usually −20 to 150° C. (preferably 0 to 120° C.). The reaction time of each step is usually 0.5 to 48 h, preferably 2 to 12 h.
- General Synthesis Method:
- Scheme A describes the general synthesis method of the compounds A9-1 and A9-2:
- Scheme B describes the general synthesis method of the compound B4:
- Scheme C describes the general synthesis method of the compound C9:
- Scheme D describes the general synthesis method of the compound D5:
- Pharmaceutical Composition and Method of Administration
- Since the compound of the present invention has excellent Syk kinases inhibitory activity and/or Syk-HDAC dual inhibitory activity, the compound of the present invention, the related deuterated compounds thereof, the possible isomers thereof (enantiomers or diastereoisomers thereof), and various crystal forms thereof, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions comprising compounds containing the present invention can be used to treat, prevent, and alleviate diseases associated with Syk or HDAC activity or expression levels. According to the prior arts, the compound of the present invention can be used to treat diseases selected from the group consisting (but not limited to) lymphoma, lymphocytic leukemia, cutaneous T-cell lymphoma, rectal cancer, breast cancer, stomach cancer, pancreatic cancer, liver cancer, lung cancer, head and neck cancer, kidney cancer, colon cancer, ovarian cancer, prostate cancer, multiple sclerosis, immunity diseases (rheumatoid arthritis and nephritis), allergic diseases (allergic rhinitis and asthma), atherosclerosis (coronary heart disease and ischemic stroke), gastrointestinal disorders, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, Alzheimer's disease, stroke and coronary artery disease, Wiskott-Aldrich syndrome, myelofibrosis, AIDS, etc.
- The pharmaceutical compositions of the present invention comprise a safe or effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. By “safe and effective amount” it is meant that the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. In general, the pharmaceutical compositions contain from 1 to 2000 mg of the compound of the invention per agent, more preferably from 5 to 200 mg of the compound of the invention per agent. Preferably, the “one dose” is a capsule or tablet.
- “Pharmaceutically acceptable carrier” means: one or more compatible solid or liquid fillers or gel materials which are suitable for human use and which must be of sufficient purity and of sufficiently low toxicity. By “compatibility” it is meant herein that the components of the composition are capable of intermingling with the compounds of the invention and with each other without significantly reducing the efficacy of the compound. Examples of pharmaceutically acceptable carriers are cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid), magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as Tween®), run Wet agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
- The mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with: (a) a filler or compatibilizer, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) a binder such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) a humectant such as glycerin; (d) a disintegrant, for example, Agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent such as paraffin; (f) an absorption accelerator, for example, a quaternary amine compound; (g) Wetting agents such as cetyl alcohol and glyceryl monostearate; (h) an adsorbent, for example, kaolin: and (i) a lubricant such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or a mixture thereof. In capsules, tablets and pills, the dosage form may also contain a buffer.
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other materials known in the art. They may contain opacifying agents and the release of the active compound or compound in such compositions may be released in a portion of the digestive tract in a delayed manner. Examples of embedding components that can be employed are polymeric and waxy materials. If necessary, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs. In addition to the active compound, the liquid dosage form may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or a mixture of these substances.
- In addition to these inert diluents, the compositions may contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
- In addition to the active compound, the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these and the like.
- Compositions for parenteral injection may comprise a physiologically acceptable sterile aqueous or nonaqueous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion. Suitable aqueous and nonaqueous vehicles, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
- Dosage forms for the compounds of the invention for topical administration include ointments, powders, patches, propellants and inhalants. The active ingredient is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or, if necessary, propellants.
- The compounds of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
- When a pharmaceutical composition is used, a safe and effective amount of a compound of the invention is administered to a mammal (e.g., a human) in need of treatment wherein the dosage is a pharmaceutically effective dosage, for a 60 kg body weight. The dose to be administered is usually from 1 to 2000 mg, preferably from 5 to 500 mg, Of course, specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
- The Main Advantages of the Present Invention are:
- 1. Provided a compound of formula I.
- 2. Provided a novel Syk kinase inhibitor and/or Syk-HDAC dual inhibitor and the preparation and use thereof. The inhibitor can inhibit the activities of Syk and HDAC kinases at very low concentrations.
- 3. Provided a pharmaceutical composition for the treatment of diseases associated with the activity of Syk or HDAC kinase.
- The present invention will be further illustrated below with reference to the specific examples. It should be understood that these examples are only to illustrate the invention but not to limit the scope of the invention. The experimental methods with no specific conditions described in the following examples are generally performed under the conventional conditions, or according to the manufacturer's instructions. Unless indicated otherwise, parts and percentage are calculated by weight.
-
- The trifluoroacetic acid salt of compound 1Ra (590 mg, 1.69 mmol) and acetaldehyde (1.30 g, 29.45 mmol) were dissolved in methanol (30 ml). Under stirring, sodium cyanoborohydride (678 mg, 10.79 mmol) was added in batches, and the temperature was controlled at below 10° C. The reaction was stirred at room temperature for 1 hour, TLC monitoring showed that the reaction was completed, then the solvent was removed under reduced pressure at room temperature. The residue was dispersed in a saturated sodium carbonate solution and extracted with ethyl acetate (25 ml×3). The combined organic layers were washed with brine and dried over anhydrous sodium sulfate. The crude product obtained by concentrating the filtrate under reduced pressure was separated by silica gel column (dichloromethane/methanol=50/1 solvent mixture elution) to obtain a yellow solid compound 1Rb (430 mg, yield 97%). 1H NMR (CDCl3, 400 MHz) δ 7.80 (dd, J=9.2 Hz, 2.8 Hz, 1H), 7.65 (d, J=2.8 Hz, 1H), 6.74 (d, J=9.2 Hz, 1H), 4.26 (dd, J=10.8 Hz, 2.8 Hz, 1H), 4.00 (dd, J=10.8 Hz, 8.4 Hz, 1H), 3.80-3.74 (m, 1H), 3.43-3.36 (m, 1H), 3.08-2.90 (m, 3H), 2.50-2.46 (m, 2H), 2.21-2.14 (m, 1H), 1.81 (dd, J=7.6 Hz, 7.2 Hz, 1H), 1.13 (t, J=7.2 Hz, 3H); MS m/z 264.2 [M+H]+.
- Compound 1Rb (408 mg, 1.55 mmol) was placed in a 50 ml single-necked flask, dissolved in methanol (3 ml), and then Pd/C (10%, 40 mg) was added. The air in the bottle was replaced with hydrogen gas, and the reaction was stirred at room temperature for 1 hour under a hydrogen atmosphere (one atmosphere). TLC monitoring showed that the reaction was completed, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a brown solid compound 1Re (361 mg, yield 99%). The compound was used in the next step without purification.
- Compound 1Rc (33 mg, 0.142 mmol) was suspended in isopropanol (2 ml), and DIPEA (55 mg, 0.426 mmol) and 6, 8-dibromo-imidazole [1,2-a] pyrazine (Compound 1a, 39 mg, 0.142 mmol) was added, then the reaction mixture was heated to 80° C. to react for 16 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by preparative thin chromatographed (dichloromethane/methanol=40/1 mixed solvent elution) to obtain pale yellow solid compound 1Rd (28 mg, 46% yield). MS m/z 429.0 [M+H]+, 431.0 [M+H]+.
- Compound 1Rd (28 mg, 0.065 mmol), Compound 1b (21 mg, 0.085 mmol) and sodium Carbonate (21 mg, 0.196 mmol) were dissolved in 1,4-dioxane/water (2 ml/0.4 ml), and then Pd(PPh3)4 (8 mg, 0.007 mmol) was added. The reaction system was replaced with argon for 3 times, then the reaction mixture was heated in a microwave reactor to 100° C. and stirred for 30 minutes. The reaction liquid was cooled to room temperature, and then poured into water and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with brine, then dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=15/1 mixed solvent elution) to obtain pale yellow solid compound 1R (6 mg, yield 20%). 1H NMR (DMSO-d6, 400 MHz) δ 13.22 (s, 1H), 9.44 (s, 1H), 8.64 (s, 1H), 8.14 (s, 1H), 8.09 (s, 1H), 7.98 (s, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.74-7.67 (m, 2H), 7.63 (s, 1H), 7.57 (d, J=2.0 Hz, 1H), 6.88 (d, J=8.8 Hz, 1H), 4.27 (dd, J=10.4 Hz, J=2.0 Hz, 1H), 3.94 (dd, J=9.8 Hz, 9.8 Hz, 1H), 3.72 (d, J=11.2 Hz, 1H), 3.03-2.97 (m, 2H), 2.92 (d, J=10.4 Hz, 1H), 2.67-2.58 (m, 1H), 2.43-2.32 (m, 2H), 2.14-2.07 (m, 1H), 1.70 (dd, J=10.8 Hz, 10.4 Hz, 1H), 1.05 (t, J=7.2 Hz, 3H); MS m/z 467.2 [M+H]+.
-
- Trifluoroacetic acid salt of compound 1Ra (150 mg, 0.43 mmol) and 1-ethoxy-1-trimethylsiloxycyclopropane (234 mg, 1.34 mmol) were dissolved in methanol (6 ml), and sodium cyanoborohydride (84 mg, 1.34 mmol) was added under stirring. The reaction system was heated to 65° C. and stirred for 16 hours, TLC monitoring shown that the reaction was completed. The reaction system was cooled to room temperature, then poured into saturated sodium carbonate solution (10 ml), and extracted with ethyl acetate (15 ml×3). The combined organic layer was washed with brine (15 ml) and dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was separated by silica gel column (dichloromethane/methanol=60/1 solvent mixture elution) to obtain a yellow solid compound 2Ra (95 mg, yield 80%). 1H NMR (CDCl3, 400 MHz) δ 7.79 (dd, J=9.2 Hz, 2.4 Hz, 1H), 7.65 (d, J=2.8 Hz, 1H), 6.73 (d, J=9.2 Hz, 1H), 4.26 (dd, J=10.8 Hz, 3.2 Hz, 1H), 3.99 (dd, J=10.8 Hz, 8.4 Hz, 1H), 3.79-3.71 (m, 1H), 3.34-3.27 (m, 1H), 3.15-3.08 (m, 1H), 3.04-2.88 (m, 2H), 2.47-2.41 (m, 1H), 2.09 (dd, J=10.4 Hz, 10.0 Hz, 1H), 1.71-1.65 (m, 1H), 0.55-0.42 (m, 4H); MS m/z 276.2 [M+H]+.
- Compound 2Ra (30 mg, 0.11 mmol) was placed in a 50 ml single-necked flask, dissolved in methanol (3 ml), and then Pd/C (10%, 10 mg) was added. The bottle was replaced with hydrogen, and the reaction was stirred at room temperature for 1 hour under a hydrogen atmosphere (one atmosphere). TLC monitoring showed that the reaction was completed, the reaction mixture was filtered, and the filtrate was spin dried to give a brown solid compound 2Rb (25 mg, yield 94%. The compound was used in the next step without purification.
- Compound 2Rb (28 mg, 0.114 mmol), 6,8-dibromo-imidazole[1,2-a]pyrazine (Compound 1a, 34 mg, 0.123 mmol) and N, N-diisopropylethylamine (29 mg, 0.225 mmol) were dissolved in isopropanol (1 ml). The reaction system was heated to 80° C. in a sealing tube and stirred for 16 hours. The reaction liquid was cooled to room temperature, and then poured into water (10 ml) and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with saturated brine (10 ml), then dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=50/1 mixed solvent elution) to obtain pale gray solid compound 2Rc (40 mg, yield 79%). MS m/z 441.0 [M+H]+, 443.0 [M+H]+.
- Compound 2Rc (40 mg, 0.091 mmol), Compound 1b (32 mg, 0.131 mmol) and sodium carbonate (24 mg, 0.226 mmol) were dissolved in 1,4-dioxane/water (1 ml/0.2 ml), and then Pd(PPh2)2 (5 mg, 0.007 mmol) was added. The reaction system was replaced with argon for 3 times, then the reaction system was heated in a microwave reactor to 100° C. and stirred for 2 hours. The reaction liquid was cooled to room temperature, and then poured into water (10 ml) and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with brine (10 ml), then dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=20/1 mixed solvent elution) to obtain yellow solid compound 2R (17 mg, yield 39%). 1H NMR (DMSO-d6, 400 MHz) δ 13.22 (s, 1H), 9.45 (s, 1H), 8.83 (s, 1H), 8.13 (s, 1H), 8.10-8.08 (m, 1H), 7.98 (d, J=0.8 Hz, 1H), 7.87-7.82 (m, 1H), 7.73-7.67 (m, 2H), 7.63 (d, J=0.8 Hz, 1H), 7.57 (d, J=2.4 Hz, 1H), 6.88 (d, J=8.8 Hz, 1H), 4.30-4.24 (m, 1H), 3.95 (dd, J=10.4 Hz, 9.2 Hz, 1H), 3.75-3.67 (m, 1H), 3.06-2.90 (m, 3H), 2.59-2.37 (m, 2H), 2.04-1.98 (m, 1H), 1.71-1.63 (m, 1H), 0.49-0.43 (m, 2H), 0.40-0.35 (m, 2H); MS m/z 479.2 [M+H]+.
-
- Compound 1Ra (430 mg, 1.83 mmol) and N,N-diisopropylethylamine (706 mg, 5.46 mmol) were dissolved in dry tetrahydrofuran (8 ml), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (551 mg, 2.37 mmol) was added under stirring. The reaction system was heated to 60° C. and stirred for 16 hours, TLC monitoring shown that the reaction was completed. The reaction system was poured into water, and extracted with ethyl acetate (15 ml×3). The combined organic layer was washed with saturated brine (15 ml) and dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was separated by silica gel column (dichloromethane/methanol=3/1 solvent mixture elution) to obtain a yellow solid compound 3Ra (550 mg, yield 95%). 1H NMR (CDCl3, 400 MHz) δ 7.80 (dd, J=9.2 Hz, 2.8 Hz, 1H), 7.66 (d, J=2.8 Hz, 1H), 6.75 (d, J=9.2 Hz, 1H), 4.25 (dd, J=10.8 Hz, 2.8 Hz, 1H), 3.99 (dd, J=11.2 Hz, 8.4 Hz, 1H), 3.81-3.75 (m, 1H), 3.48-3.41 (m, 1H), 3.10-2.95 (m, 5H), 2.70-2.63 (m, 1H), 2.31 (dd, J=10.8 Hz, 10.8 Hz, 1H); MS m/z 318.2 [M+H]+.
- Compound 3Ra (300 mg, 0.95 mmol) was placed in a 50 ml single-necked flask, dissolved in methanol (15 ml), and then Pd/C (10%, 50 mg) was added. The bottle was replaced with hydrogen, and the reaction was stirred at room temperature for 1 hour under a hydrogen atmosphere (one atmosphere). TLC monitoring showed that the reaction was completed, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a brown solid compound 3Rb (250 mg, yield 92%).
- Compound 3Rb (35 mg, 0.122 mmol), 6,8-dibromo-imidazole[1,2-a]pyrazine (Compound 1a, 41 mg, 0.148 mmol) and N, N-diisopropylethylamine (31 mg, 0.240 mmol) were dissolved in isopropanol (1 ml). The reaction system was heated to 80° C. in a sealing tube and stirred for 16 hours. The reaction liquid was cooled to room temperature, and then poured into water and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with brine (10 ml), then dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=70/1 mixed solvent elution) to obtain gray solid compound 3Rc (45 mg, yield 76%). MS m/z 483.0 [M+H]+, 485.0 [M+H]+.
- Compound 3Rc (45 mg, 0.093 mmol), 1b (34 mg, 0.139 mmol) and sodium carbonate (24 mg, 0.236 mmol) were dissolved in 1,4-dioxane/water (1 ml/0.2 ml), and then Pd(PPh2)2 (5 mg, 0.007 mmol) was added. The reaction system was replaced with argon for 3 times, then the reaction system was heated in a sealing tube to 100° C. and stirred for 16 hours. The reaction liquid was cooled to room temperature, and then poured into water (10 ml) and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with saturated brine (10 ml), then dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=15/1 mixed solvent elution) to obtain yellow solid compound 3R (25 mg, yield 52%). 1H NMR (DMSO-d6, 400 MHz) δ 13.22 (s, 1H), 9.47 (s, 1H), 8.64 (s, 1H), 8.13 (s, 1H), 8.09 (s, 1H), 7.98 (s, 1H), 7.87-7.82 (m, 1H), 7.73-7.67 (m, 2H), 7.63 (d, J=0.8 Hz, 1H), 7.59 (d, J=2.4 Hz, 1H), 6.90 (d, J=8.8 Hz, 1H), 4.30-4.22 (m, 1H), 3.97-3.89 (m, 1H), 3.77-3.70 (m, 1H), 3.33-3.24 (m, 2H), 3.08-2.94 (m, 3H), 2.70-2.56 (m, 2H), 2.24-2.18 (m, 1H); MS m/z 521.2 [M+H]+.
-
- Compound 1Ra (970 mg, 4.12 mmol) and N-methyl-4-piperidone (933 mg, 8.24 mmol were dissolved in methanol (35 ml), and acetic acid (247 mg, 4.12 mmol) was added under stirring, and then sodium cyanoborohydride (776 mg, 12.35 mmol) was added in batches. The temperature was controlled below 10° C. The reaction system was stirred at room temperature for 16 hour, TLC monitoring showed that the reaction was completed, then the solvent was removed under reduced pressure at room temperature. The residue was dispersed in a saturated sodium carbonate solution and extracted with ethyl acetate (25 ml×3). The combined organic layer was washed with saturated brine (20 ml) and dried over anhydrous sodium sulfate. The residue obtained by concentrating the filtrate under reduced pressure was separated by silica gel column (dichloromethane/methanol=20/1 solvent mixture elution) to obtain yellow solid compound 4Ra (860 mg, yield 63%). MS m/z 333.2 [M+H]+.
- Compound 4Ra (373 mg, 1.12 mmol) was placed in a 50 ml single-necked flask, dissolved in methanol (7 ml), and then Pd/C (10%, 40 mg) was added. The bottle was replaced with hydrogen, and the reaction was stirred at room temperature for 2 hours under a hydrogen atmosphere. TLC monitoring showed that the reaction was completed, then the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give crude product, which was separated by silica gel column (dichloromethane/methanol/aqueous ammonia=10/1/0.25 mixed solvent elution) to provide brown solid compound 4Rb (150 mg, yield 44%). MS m/z 303.3 [M+H]+.
- Compound 4Rb (34 mg, 0.113 mmol) was suspended in isopropanol (2 ml), and DIPEA (29 mg, 0.225 mmol) and 6,8-dibromo-imidazole [1,2-a] pyrazine (31 mg, 0.113 mmol) was added, then the reaction mixture was heated to 80° C. to react for 4 hours. The reaction mixture was cooled to room temperature. The residue obtained by concentration under reduced pressure was purified by preparative thin chromatographe (dichloromethane/methanol=15/1 mixed solvent elution) to obtain brown solid compound 4Rc (28 mg, 50% yield). MS m/z 498.0 [M+H]+, 500.0 [M+H]+.
- Compound 4Rc (28 mg, 0.056 mmol), compound 1b (27 mg, 0.112 mmol) and sodium carbonate (18 mg, 0.169 mmol) were dissolved in 1,4-dioxane/water (1 ml/0.2 ml), and then Pd(PPh3)4 was added (6 mg, 0.006 mmol). The reaction system was replaced with argon for 3 times, then the reaction mixture was heated in a microwave reactor to 135° C. and stirred for 1 hour. The reaction liquid was cooled to room temperature, and then poured into water (10 ml) and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with saturated brine (10 ml), then dried over anhydrous sodium sulfate and filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=5/1 mixed solvent elution) to obtain pale pale yellow solid compound 4R (7 mg, yield 23%). 1H NMR (DMSO-d6, 400 MHz) δ 13.22 (s, 1H), 9.44 (s, 1H), 8.64 (s, 1H), 8.13 (s, 1H), 8.09 (s, 1H), 7.98 (d, J=0.8 Hz, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.73-7.67 (m, 2H), 7.63 (d, J=0.8 Hz, 1H), 7.57 (d, J=2.0 Hz, 1H), 6.87 (d, J=8.8 Hz, 1H), 4.26 (dd, J=10.4 Hz, J=2.4 Hz, 1H), 3.94 (dd, J=10.4 Hz, 9.2 Hz, 1H), 3.72 (d, J=11.6 Hz, 1H), 3.04-2.90 (m, 3H), 2.86-2.78 (m, 2H), 2.63-2.55 (m, 1H), 2.38-2.28 (m, 2H), 2.23-2.11 (m, 4H), 1.95-1.85 (m, 2H), 1.80-1.71 (m, 2H), 1.49-1.38 (m, 2H); MS m/z 536.4 [M+H]+.
-
- Compound 1Ra (600 mg, 2.55 mmol) and tetrahydropyrone (511 mg, 5.10 mmol) were dissolved in methanol (25 ml), and acetic acid (153 mg, 2.55 mmol) was added under stirring, and then sodium cyanoborohydride (481 mg, 7.65 mmol) was added in batches. The temperature was controlled below 10° C. The reaction system was stirred at room temperature overnight, TLC monitoring showed that the reaction was completed, then the solvent was removed under reduced pressure at room temperature. The residue was dispersed in a saturated sodium carbonate solution and extracted with ethyl acetate (20 ml×3). The combined organic layer was washed with saturated brine (20 ml) and dried over anhydrous sodium sulfate. The residue obtained by concentrating the filtrate was separated by silica gel column (dichloromethane/methanol=30/1 solvent mixture elution) to obtain yellow solid compound 5Ra (800 mg, yield 98%). MS m/z 320.2 [M+H]+.
- Compound 4Ra (200 mg, 0.63 mmol) was placed in 50 ml single-necked flask, dissolved in methanol (5 ml), and then Pd/C (10%, 30 mg) was added. The bottle was replaced with hydrogen, and the reaction was stirred at room temperature for 1 hour under a hydrogen atmosphere. TLC monitoring showed that the reaction was completed, then the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give crude product, which was separated by silica gel column (dichloromethane/methanol=30/1 mixed solvent elution) to provide brown solid compound 5Rb (80 mg, yield 44%). MS m/z 290.2 [M+H]+.
- Compound 5Rb (30 mg, 0.104 mmol) was suspended in isopropanol (2 ml), and DIPEA (27 mg, 0.208 mmol) and 6,8-dibromo-imidazole [1,2-a] pyrazine (29 mg, 0.104 mmol) was added, then the reaction mixture was heated to 80° C. to react for 16 hours. The reaction mixture was cooled to room temperature. The residue obtained by concentration under reduced pressure was purified by preparative thin chromatography (dichloromethane/methanol=15/1 mixed solvent elution) to obtain pale yellow solid compound 5Rc (43 mg, 86% yield). MS m/z 485.1 [M+H]+, 487.1 [M+H]+.
- Compound 5Rc (43 mg, 0.089 mmol), compound 1b (43 mg, 0.178 mmol) and sodium carbonate (28 mg, 0.267 mmol) were dissolved in 1,4-dioxane/water (1 ml/0.2 ml), and then Pd(PPh3)4 was added (10 mg, 0.009 mmol). The reaction system was replaced with argon for 3 times, then the reaction mixture was heated in a microwave reactor to 135° C. and stirred for 1 hour. The reaction liquid was cooled to room temperature, and then poured into water (10 ml) and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with saturated brine (10 ml), then dried over anhydrous sodium sulfate and filtered.
- The residue obtained by concentrating the filtrate under reduced pressure was purified by preparative chromatography (methylene chloride/methanol=15/1 mixed solvent elution) to obtain pale yellow solid compound 5R (21 mg, yield 45%). 1H NMR (DMSO-d6, 400 MHz) δ 13.22 (s, 1H), 9.45 (s, 1H), 8.64 (s, 1H), 8.14 (s, 1H), 8.09 (s, 1H), 7.98 (d, J=0.8 Hz, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.73-7.66 (m, 2H), 7.63 (d, J=0.8 Hz, 1H), 7.57 (d, J=2.4 Hz, 1H), 6.88 (d, J=9.2 Hz, 1H), 4.27 (dd, J=10.4 Hz, 2.0 Hz, 1H), 3.98-3.87 (m, 3H), 3.73 (d, J=11.2 Hz, 1H), 3.30-3.24 (m, 2H), 3.06-2.91 (m, 3H), 2.63-2.55 (m, 1H), 2.47-2.39 (m, 1H), 2.36-2.28 (m, 1H), 1.90 (dd, J=11.2 Hz, 11.2 Hz, 1H), 1.77-1.72 (m, 2H), 1.49-1.37 (m, 2H); MS m/z 523.2 [M+H]+.
-
- Compound 6a (300 mg, 1.45 mmol) and 6b (356 mg, 2.17 mmol) were dissolved in tetrahydrofuran (10 ml). The reaction was stirred at room temperature 4 hours, then NaBH3CN (273 mg, 4.34 mmol) was added to the reaction system in batches. The reaction system was stirred at room temperature in sealed state for 16 hours. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (30 ml), and extracted with ethyl acetate (15 ml×3), and then washed with saturated brine (10 ml×2). The ethyle acetate layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by column chromatography (petroleum ether/ethyl acetate=10/1 to 4/1) to give a yellow solid compound 6c (170 mg, yield 33%). 1H NMR (CDCl3, 400 MHz) δ 8.14-8.10 (m, 1H), 8.03-8.00 (m, 1H), 7.45-7.42 (m, 2H), 6.81 (dd, J=7.2 Hz, 2.0 Hz, 2H), 3.92 (s, 3H), 3.62 (s, 2H), 3.43 (t, J=5.2 Hz, 4H), 2.60 (t, J=5.2 Hz, 4H); MS m/z 356.3 [M+H]+.
- Compound 6c (150 mg, 0.42 mmol) was dissolved in methanol (5 ml), then Pd/C (10%, 50 mg) was carefully added to the reaction system, and then replaced with hydrogen for three times. The reaction solution was stirred under room temperature to react for 16 hours. After LCMS detected that the reaction was completed, the mixture was filtered through celite, washed with anhydrous methanol, and the filtrate was concentrated under reduced pressure to provide pale yellow solid compound 6d (100 mg, yield 73%). MS m/z 326.3 [M+H]+.
- Compound 1a (170 mg, 0.62 mmol), 6d (100 mg, 0.31 mmol) and DIPEA (80 mg, 0.62 mmol) were added to isopropanol (4 ml). The reaction system was heated to 80° C. and stirred to react in a sealed system for 16 hours. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (10 ml), and extracted with ethyl acetate (10 ml×3), and then washed with saturated brine (5 ml×2). The ethyl acetate layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by column chromatography (petroleum ether/ethyl acetate=10/1 to 2/1 solvent mixture) to give a brown solid compound 6e (150 mg, yield 47%). 1H NMR (CDCl3, 400 MHz) δ 8.03-7.99 (m, 3H), 7.71 (d, J=8.8 Hz, 2H), 7.67 (s, 1H), 7.53 (d, J=0.8 Hz, 1H), 7.49 (d, J=0.8 Hz, 1H), 7.45 (d, J=8.0 Hz, 2H), 6.97 (d, J=9.2 Hz, 2H), 3.92 (s, 3H), 3.62 (s, 2H), 3.21-3.17 (m, 4H), 2.65-2.61 (m, 4H); MS m/z 521.2 [M+H]+; 523.2 [M+H]+.
- Compound 6e (140 mg, 0.27 mmol), 1b (132 mg, 0.54 mmol), Pd(PPh3)4 (31 mg, 0.027 mmol) and Na2CO3 (67 mg, 0.54 mmol) were added into dioxane/water (4 ml/0.4 ml). The reaction solution was heated by microwave condition to 135° C. and stirred to react for 1 hours. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (10 ml), and extracted with ethyl acetate (10 ml×3), and then washed with saturated brine (5 ml×2). The ethyl acetate layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by preparative thin layer chromatography (petroleum ether/ethyl acetate=1/1 solvent mixture) to give a brown solid compound 6f (80 mg, yield 53%). MS m/z 559.3 [M+H]+.
- Compound 6f (35 mg, 0.063 mmol) was added to methanol (0.5 mL), and then aqueous hydroxylamine solution (2 ml) was added into the reaction solution. The reaction solution was heated to 30° C. and stirred to react for 4 hours. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (5 ml), and extracted with ethyl acetate (5 ml×3), and then washed with saturated brine (2 ml×2). The ethyl acetate layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by preparative thin layer chromatography (CH2Cl2/MeOH=10/1 solvent mixture) to give a gray solid compound 6 (10 mg, yield 28%). 1H NMR (DMSO-d6, 400 MHz) δ 13.19 (s, 1H), 11.19 (s, 1H), 9.52 (s, 1H), 9.02 (s, 1H), 8.67 (s, 1H), 8.18 (s, 1H), 8.09 (s, 1H), 8.02-7.98 (m, 3H), 7.83 (d, J=8.8 Hz, 1H), 7.75-7.70 (m, 3H), 7.64 (s, 1H), 7.43 (d, J=8.0 Hz, 2H), 6.99 (d, J=9.2 Hz, 2H), 3.59 (s, 2H), 3.18-3.11 (m, 4H), 2.58-2.50 (m, 4H); MS m/z 560.3 [M+H]+.
-
- Compound 6a (250 mg, 1.20 mmol), 7a (339 mg, 1.80 mmol), HATU (913 mg, 2.40 mmol) and triethylamine (364 mg, 3.60 mmol) were added to N,N-dimethylformamide (10 ml), and the reaction mixture was stirred at room temperature for 4 hours. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (30 ml), and extracted with ethyl acetate (15 ml×4), and then washed with saturated brine (20 ml). The organic phase was dried with anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford yellow liquid compound 7b (350 mg, yield 77%). MS m/z 378.2 [M+H]+.
- Compound 7b (340 mg, 0.90 mmol) was dissolved in methanol (10 ml), then Pd/C (100 mg) was carefully added to the reaction system, and then replaced with hydrogen for three times. The reaction solution was stirred under room temperature to react for 2 hours. After LCMS detected that the reaction was completed, the filter cake was filtered through celite, washed with anhydrous methanol, and the organic layer was concentrated under reduced pressure to provide pale yellow solid compound 7c (250 mg, yield 80%). MS m/z 348.3 [M+H]+.
- Compound 1a (200 mg, 0.72 mmol), 7c (201 mg, 0.59 mmol) and DIPEA (153 mg, 1.18 mmol) were added to isopropanol (8 ml). The reaction mixture was heated to 80° C. in sealed tube and stirred to react overnight. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (20 ml), and extracted with ethyl acetate (15 ml×3), and then washed with saturated brine (10 ml×2). The organic layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by column chromatography (petroleum ether/ethyl acetate=10/1 to 3/1 solvent mixture) to give a brown liquid compound 7d (200 mg, yield 51%). 1H NMR (CDCl3, 400 MHz) δ 8.03 (s, 1H), 7.74 (d, J=9.2 Hz, 2H), 7.69 (s, 1H), 7.54 (d, J=0.8 Hz, 1H), 7.50 (d, J=1.2 Hz, 1H), 6.97 (d, J=9.2 Hz, 2H), 3.81-3.76 (m, 2H), 3.67 (s, 3H), 3.66-3.60 (m, 2H), 3.19-3.10 (m, 4H), 2.37 (t, J=8.0 Hz, 2H), 2.32 (t, J=7.6 Hz, 2H), 1.69-1.60 (m, 2H), 1.50-1.42 (m, 4H), 1.40-1.32 (m, 2H); MS m/z 543.3 [M+H]+, 545.3 [M+H]+.
- Compound 7d (200 mg, 0.37 mmol), 1b (180 mg, 0.74), Pd(PPh3)4 (43 mg, 0.037 mmol) and sodium carbonate (78 mg, 0.74 mmol) were added to dioxane/water (8 ml/1 ml). The reaction mixture was heated by microwave condition to 135° C. and stirred to react for 1 hour. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (15 ml), and extracted with ethyl acetate (10 ml×3), and then washed with saturated brine (10 ml×2). The organic layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by preparative thin layer chromatography (petroleum ether/ethyl acetate=1/1 solvent mixture) to give gray liquid compound 7e (75 mg, yield 35%). MS m/z 581.2 [M+H]+.
- Compound 7e (50 mg, 0.086 mmol) was dissolved in methanol (2 ml), and aqueous lithium hydroxide solution (1 N, 1 ml) was added dropwise, and the reaction mixture was stirred at room temperature to react for 16 hrs. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (4 ml), and extracted with ethyl acetate (5 ml×6), and then washed with saturated brine (3 ml×2). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford brown solid compound 7f (50 mg). The compound was used in the next step reaction without further purification. MS m/z 567.4 [M+H]+.
- Compound 7f (50 mg, 0.086 mmol), 7g (21 mg, 0.18 mmol), EDCI (34 mg, 0.18 mmol), HOBT(24 mg, 0.18 mmol) and triethylamine (18 mg, 0.18 mmol) were added to tetrahydrofuran (3 ml). The reaction mixture was stirred at room temperature to react for 2 days. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (6 ml), and extracted with ethyl acetate (5 ml×5), and then washed with saturated brine (10 ml×2). The organic layer was dried over anhydrous sodium sulfate and filtered, and the residue obtained by concentrating the filtrate under reduced pressure was purified by preparative thin layer chromatography (petroleum ether/ethyl acetate=2/1 solvent mixture) to give a brown solid compound 7h (45 mg, yield of two steps was 69%). 1H NMR (DMSO-d6, 400 MHz) δ 13.19 (s, 1H), 10.90 (s, 1H), 9.56 (s, 1H), 8.67 (s, 1H), 8.19 (s, 1H), 8.09 (s, 1H), 8.04 (d, J=8.8 Hz, 2H), 7.99 (d, J=1.2 Hz, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.72 (dd, J=8.8 Hz, 0.8 Hz, 1H), 7.64 (d, J=0.8 Hz, 1H), 7.02 (d, J=9.2 Hz, 2H), 4.82-4.78 (s, 1H), 3.94-3.87 (m, 1H), 3.65-3.59 (m, 4H), 3.51-3.45 (m, 1H), 3.18-3.05 (m, 4H), 2.35 (t, J=7.4 Hz, 2H), 1.98 (t, J=7.4 Hz, 2H), 1.70-1.58 (m, 3H), 1.57-1.43 (m, 7H), 1.31-1.20 (m, 4H).
- The compound 7h (40 mg, 0.06 mmol) was dissolved in tetrahydrofuran (1 ml), and then 4N HCl dioxane solution (1 ml) was slowly added dropwise at room temperature. The reaction mixture was stirred under room temperature to react for 2 hours. LCMS monitored that the reaction was completed, then the reaction mixture was concentrated under reduced pressure. The crude product was pulped and washed with acetonitrile and diethyl ether. The product was dissolved in DMSO and added to deionized water, and lyophilized to give a brown solid compound 7 (25.6 mg, yield 73%). 1H NMR (DMSO-d6, 400 MHz) δ 10.61 (br s, 1H), 10.37 (br s, 1H), 8.88 (s, 1H), 8.27-8.20 (m, 3H), 8.19-8.09 (m, 4H), 7.91 (d, J=8.4 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.43-7.30 (m, 2H), 5.20-6.20 (br, 1H), 3.82-3.70 (m, 4H), 3.36-3.22 (m, 4H), 2.37 (t, J=7.6 Hz, 2H), 1.95 (t, J=7.2 Hz, 2H), 1.56-1.43 (m, 4H), 1.34-1.20 (m, 4H); MS m/z 582.2 [M+H]+.
-
- Compound 8Ra (200 mg, 0.60 mmol) was dissolved in dichloromethane (10 ml), and trifluoroacetic acid was added to the reaction system (1.5 ml) and stirred at room temperature for 2 hours. Under 40° C., the mixture was concentrated under reduced pressure to remove trifluoroacetic acid. The residue obtained was dissolved in dichloromethane (10 ml), and ethyl sulfonyl chloride (116 mg, 0.90 mmol) and triethylamine (121 mg, 1.20 mmol) was added thereto, and stirred at room temperature for 16 hours. The reaction mixture was washed with water (10 ml×2), then the organic phase was dried over anhydrous magnesium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain the filtrate, which was purified by normal phase silica gel column chromatography (dichloromethane/ethyl acetate=1:1) to provide yellow solid 8Rb (150 mg, yield 77%). MS m/z 328.0 [M+H]+.
- Compound 8Rb (150 mg, 0.46 mmol) was dissolved in methanol (10 ml), and Pd/C (10%, 25 mg) was subsequently added. The reaction mixture was stirred at room temperature for 2 hours, filtered and the filtrate was collected, and washed with dichloromethane/methanol (10:1) until the product was completely eluted. The combined filtrate was concentrated under reduced pressure to give gray solid compound 8Rc (100 mg, yield 73%). 1H NMR (DMSO-d6, 400 MHz) δ 6.61 (d, J=8.4 Hz, 1H), 6.09 (dd, J=8.4 Hz, 2.0 Hz, 1H), 6.03 (d, J=2.4 Hz, 1H), 4.56 (br s, 2H), 4.22 (dd, J=10.4 Hz, 2.4 Hz, 1H), 3.82 (dd, J=10.4 Hz, 9.2 Hz, 1H), 3.70 (d, J=12.4 Hz, 1H), 3.59 (dd, J=10.0H, 10 Hz, 2H), 3.10 (q, J=7.2 Hz, 2H), 3.01-2.95 (m, 1H), 2.91-2.82 (m, 1H), 2.70-2.55 (m, 2H), 1.22 (t, J=7.2 Hz, 3H); MS m/z 298.0 [M+H]+.
- Compound 1a (110 mg, 0.40 mmol), 8Rc (80 mg, 0.27 mmol) and DIPEA (70 mg, 0.54 mmol) were added into isopropanol (3 ml). The reaction mixture was heated in a sealed tube to 80° C. and stirred to react for 16 hrs. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (8 ml), and extracted with ethyl acetate (5 ml×4). The combined organic layers were washed with saturated brine (50 ml×2), dried over anhydrous sodium sulfate and filtered. The residue obtained by concentrating the filtrate was purified by preparative thin layer chromatography (CH2Cl2/MeOH=20/1) to give pale yellow solid compound 8Rd (80 mg, yield 40%). MS m/z 493.1 [M+H]+, 495.1 [M+H]+.
- Compound 8Rd (20 mg, 0.038 mmol), 1b (19 mg, 0.076 mmol), Pd(dppf)Cl2 (2.8 mg, 0.0038 mmol) and potassium carbonate (11 mg, 0.076 mmol) were added to dioxane/water (1 ml/0.1 ml). The reaction mixture was heated under microwave conditions to 135° C. and stirred to react for 1 hour. Then 1b (9.3 mg, 0.038 mmol), Pd(dppf)Cl2 (2.8 mg, 0.0038 mmol) and potassium carbonate (5.3 mg, 0.038 mmol) were added, and the reaction was heated under microwave conditions to 135° C. and stirred to react for 1 hour. LCMS monitored that the reaction was completed, then the reaction liquid was poured into water (4 ml), and extracted with ethyl acetate (3 ml×5), and then washed with saturated brine (2 ml×2), dried over anhydrous sodium sulfate and filtered. The residue obtained by concentrating the filtrate was purified by preparative thin layer chromatography (dichloromethane/ethyl acetate=2/1 to give the product, and then pulped with methanol and diethyl ether for two times to provide brown solid compound 8R (5.9 mg, yield 27%). 1H NMR (DMSO-d6, 400 MHz) δ 13.23 (s, 1H), 9.51 (s, 1H), 8.65 (s, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.74-7.70 (m, 2H), 7.66-7.60 (m, 2H), 6.95 (d, J=8.8 Hz, 1H), 4.39-4.34 (m, 1H), 3.99-3.89 (m, 2H), 3.72-3.63 (m, 2H), 3.18-2.99 (m, 4H), 2.74-2.65 (m, 2H), 1.24 (t, J=7.2 Hz, 3H). MS m/z 531.2 [M+H]+.
-
- Compound 1Ra trifluoroacetate (500 mg, 1.43 mmol) and DIPEA (554 mg, 4.29 mmol) were added to dichloromethane (20 ml), and then trifluoroacetic anhydride (601 mg, 2.86 mmol) was added slowly at room temperature. The reaction mixture was stirred at room temperature for 2 hours. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (50 ml), and extracted with dichloromethane (20 ml×4). The combined organic phase was washed with saturated brine (10 ml×2), dried with anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure. The residue was separated and purified by preparative thin layer chromatography (petroleum ether/ethyl acetate=2/1) to provide yellow solid compound 9Ra (320 mg, yield 68%). 1H NMR (CDCl3, 400 MHz) δ 7.86-7.80 (m, 1H), 7.70 (d, J=2.4 Hz, 1H), 6.82 and 6.78 (two d, J=9.2 Hz, 8.8 Hz, 1H), 4.71-4.65 and 4.60-4.55 (two m, 1H), 4.39-4.33 (m, 1H), 4.19-3.90 (m, 3H), 3.52-3.36 (m, 2H), 3.19-3.00 (m, 2H), 2; MS m/z 332.2 [M+H]+.
- Compound 9Ra (200 mg, 0.60 mmol) was dissolved in methanol (6 ml), then Pd/C (10%, 100 mg) was carefully added to the reaction system and replaced with hydrogen for three times. The reaction mixture was stirred to react at room temperature for 2 hours. After LCMS detected that the reaction was completed, the mixture was filtered through celite, and the filter cake was washed with anhydrous methanol. The combined organic layer was concentrated under reduced pressure to provide brown solid compound 9Rb (170 mg, yield 93%). MS m/z 302.3 [M+H]+.
- Compound 1a (291 mg, 1.06 mmol), 9Rb (160 mg, 0.53 mmol) and DIPEA (137 mg, 1.06 mmol) were added to isopropanol (8 ml), and the reaction mixture was heated in a sealed tube to 80° C. and stirred to react for 4 hrs. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (20 ml), and extracted with ethyl acetate (10 ml×3). The combined organic layer was washed with saturated brine (5 ml×2), dried over anhydrous sodium sulfate and filtered. The residue obtained by concentrating the filtrate under reduced pressure was purified by preparative thin layer chromatography (dichloromethane/methanol=10/1) to give a brown solid compound 9Rc (120 mg, yield 45%). MS m/z 497.2 [M+H]+, 499.2 [M+H]+.
- Compound 9Rc (27 mg, 0.054 mmol), 1b (26 mg, 0.108), Pd(dppf)Cl2 (4 mg, 0.0054 mmol) and sodium carbonate (13 mg, 0.108 mmol) were added to dioxane/water (1 ml/0.1 ml). The reaction mixture was heated by microwave condition to 100° C. and stirred to react for 1 hour. LCMS monitored that the reaction was completed, then the reaction mixture was poured into water (3 ml), and extracted with ethyl acetate (2 ml×3). The combined organic layer was washed with saturated brine (2 ml×2), dried over anhydrous sodium sulfate and filtered. The residue obtained by concentrating the filtrate under reduced pressure was purified by preparative thin layer chromatography (dichloromethane/methanol=1/1) to give pale yellow solid compound 9 (2 mg, yield 7%). 1H NMR (DMSO-d6, 400 MHz) δ 13.24 (s, 1H), 9.53 (s, 1H), 8.65 (s, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.76-7.68 (m, 2H), 7.66-7.61 (m, 2H), 7.00-6.90 (m, 1H), 4.46-4.33 (m, 2H), 4.05-3.90 (m, 3H), 3.25-3.10 (m, 2H), 2.85-2.64 (m, 2H); MS m/z 535.2 [M+H]+.
-
- 6-Bromoindazole (0.5 g, 2.54 mmol), bis(pinacolato)diboron (0.7 g, 2.79 mmol) and potassium acetate (0.7 g, 7.62 mmol) were dissolved in dimethyl sulfoxide (15 mL). After replaced with nitrogen for three times, Pd(dppf)Cl2.DCM (310 mg, 0.38 mmol) was added to the system, and heated to 90° C. under nitrogen atmosphere to reflux for 16 hours. TLC monitored that the raw material disappeared, and product was formed. The reaction was cooled to room temperature, and ethyl acetate (25 ml) and water (25 ml) were added to dilute the reaction solution and filtered. The filter cake was soaked with ethyl acetate (15 mL) and discarded. The filtrate was separated, and the combined organic layer was concentrated to dry to provide crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/hexane=1/50 to 30) to give an off-white solid compound 1b (384 mg, purity 96.8%, yield 62.0%). MS m/z 245.1 [M+H]+.
- 10a (0.2 g, 1.46 mmol), PyBOP (0.8 g, 1.60 mmol) and triethylamine (0.3 mL) were dissolved in N,N-dimethylformamide (3.6 mL), after replaced with nitrogen for 3 times, O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (0.2 g, 1.75 mmol) was added and reacted at 15 to 25° C. for 5 hours. HPLC showed that the compound 10a was consumed, water (7.2 ml) was added, the aqueous phase was extracted with ethyl acetate (20 ml×3), and the combined organic phase was concentrated to dry to give the crude product. The crude product was purified by silica gel column chromatography (methanol/dichloromethanol=1/100 to 30) to give an off-white solid 1b (213 mg, purity 91.5%, yield 61.6%). MS m/z 153.0 [M-THP+H]+.
- 1a (0.5 g, 1.80 mmol), 10b (0.5 g, 1.98 mmol) were dissolved in isopropyl alcohol (12.5 ml), after replaced with nitrogen for three times, N,N-diisopropylethylamine (0.6 ml) was added, and the mixture was heated to 80° C. to react for 7 days. The reaction solution was concentrated under reduced pressure to give the crude product. The crude product was purified by preparative thin layer chromatography (methanol/dichloromethane=1/30) to give an off-white solid 10c (46 mg, 86.5% purity). MS m/z 432.1 [M+H]+.
- 10c (0.5 g, 1.15 mmol), 1b (0.3 g, 1.4 mmol) and potassium carbonate (0.3 g, 2.3 mmol) were dissolved in dioxane (7.5 ml) and water (2.5 ml). After replaced with nitrogen for 3 times, Pd(dppf)Cl2.DCM (95 mg, 0.1 mmol) was added, and after replaced with nitrogen for 3 times, warmed to 90° C. to react for 7 hours. The reaction was cooled to room temperature, and ethyl acetate (50 mL) was added, filtered, and the filtrate was concentrated to dryness.
- The crude product was purified by silica gel column chromatography (methanol/dichloromethane=1/50), the resulting solid was pulped with methanol (2 ml) to provide off-white solid 10d (120 mg, 91.6% purity). MS m/z 470.4 [M+H]+.
- 10d (0.1 g, 0.2 mmol) was dissolved in methanol (10 mL), and trifluoroacetic acid (0.5 mL) was added and reacted at 15 to 25° C. for 16 hours. The reaction mixture was concentrated to dryness under reduced pressure, methanol (2 ml) was added to pulp so as to give brown solid 10 (41 mg, 95.6% purity, 50% yield). 1H NMR (400 MHz, DMSO-d6): δ 11.12 (s, 1H), 10.02 (s, 1H), 8.82 (s, 1H), 8.26-8.29 (d, J=8.7 Hz, 2H), 8.22 (s, 1H), 8.07-8.11 (d, J=15.8 Hz, 2H), 7.82 (m, 3H), 7.75 (d, J=8.3 Hz, 2H). MS m/z 386.3 [M+H]+.
-
- To a 250 ml three-necked bottle, p-chloronitrobenzene (11b, 5.0 g, 31.8 mmol), dimethyl sulfoxide (50.2 ml), morpholine (2.8 g, 38.2 mmol) and potassium carbonate (6.6 g, 47.7 mmol) was added. The system was replaced with nitrogen for three times, and the reaction was heated to 100° C. and stirred to react for 24 hours. The system was cooled to room temperature, and water (150 ml) was added to the reaction mixture, and a large amount of solid was precipitated from the reaction mixture, After filtration, the filter cake was added into ethyl acetate (40 mL) and heated with stirring to make the filter completely dissolved to form a solution. To the resulting solution, petroleum ether (100 ml) was slowly added dropwise within 30 minutes. Then the reaction system was cooled at 0° C. for 1 hour for crystallization. After filtration, the filter cake was dried in a vacuum oven at 60° C. for 6 hours to constant weight to obtain bright yellow solid material tic (5.6 g, purity 99.4%, yield 84.9%). MS m/z 209.1 [M+H]+.
- 11c (0.6 g, 2.9 mmol) was dissolved in tetrahydrofuran (12.5 ml), and methanol (12.5 ml) was added and stirred for 5 min. Ammonium chloride (1.5 g, 28.8 mmol) in water (6.5 mL) was added and the mixture was continued to stir for 30 min. Zinc powder (942 mg, 14.4 mmol) was added to the system and the reaction was continued to stir at 17° C. for 3 hours. The reaction liquid was gradually changed from bright yellow to gray, and the reaction was monitored to have been finished by thin-plate chromatography (methanol/dichloromethane=1:10). After stood for 15 minutes, the reaction was filtered through celite, the cake was rinsed with ethyl acetate (10.5 ml) and the filtrate was concentrated to dryness under reduced pressure. Water was added (5.5 ml) and extracted with ethyl acetate (10 ml×3). The combined organic phase was washed with saturated sodium chloride solution (10.2 mL), dried and concentrated under reduced pressure to give a pale yellow solid 11d (500 mg, 99.1% purity, yield 97.4%).
- 11d (0.5 g, 2.8 mmol), 1a (0.8 g, 2.8 mmol), isopropanol (5.1 ml), and diisopropylethylamine (0.7 g, 5.6 mmol) were added to a 25 ml three-necked flask. The system was replaced with nitrogen for three times under stirring. The system was refluxed for 16 hours in 100° C. oil bath. The system was cooled to 17° C., and concentrated to dryness under reduced pressure, purified by silica gel column chromatography (ethyl acetate/n-hexane=1/10 to 1:3) to give light yellow solid Compound 11e (0.7 g, 99.5% purity, yield 72.6%). MS m/z 374.0 [M+H]+.
- 11h (0.9 g, 3.7 mmol), 1-hydroxybenzotriazole (0.5 g, 3.7 mmol) and N,N-dimethylformamide (4.1 mL) were sequentially added to a 25 mL single-necked flask. After cooled to 0° C., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.8 g, 4.4 mmol) and diisopropylethylamine (0.9 g, 7.4 mmol) were added, stirred for 20 minutes and warmed to 13° C. 11g (0.4 g, 3.7 mmol) was added and the reaction was continued to stirred. The reaction was monitored by thin layer chromatography (ethyl acetate: n-hexane=1:1) until the starting material disappeared. After water (8.1 ml) was added to the reaction mixture, the mixture was extracted with ethyl acetate (10 mL×3), the combined organic phase was washed with saturated sodium chloride solution (10.2 ml), and concentrated to dry under reduced pressure. The crude product was purified by silica gel column product (ethyl acetate: n-hexane=4:1) to give a white solid compound 11f (1.0 g, purity 74.4%, yield 79.9%). MS m/z 257.0 [M-pinacol+H]+.
- 11e (240 mg, 0.6 mmol), 1,4-dioxane (3.6 ml), potassium carbonate (178 mg, 1.3 mmol), water (1.2 ml), 11f (118 mg, 0.6 mmol) and Pd(dppf)Cl2.DCM (46 mg, 0.06 mmol) were added in a 25 ml three-necked flask, and the system was replaced with nitrogen gas for three times. The system was heated to 90° C. so as to reflux for 16 hours. HPLC showed that the reaction was completed, and the reaction mixture was cooled to 17° C. and concentrated to dry under reduced pressure. The crude product was purified by preparative thin-layer chromatography (methanol/dichloromethane=1/15, Rf=0.3), and then the silica gel containing the product band was passed through a flash column (550 ml, methanol/dichloromethane=1/10) so as to obtain an off-white solid 11 (35 mg, purity 96.5%). 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H), 9.56 (s, 1H), 8.72 (s, 1H), 8.63 (s, 1H), 8.20 (d, J=7.8 Hz, 1H), 8.07-7.88 (m, 4H), 7.64 (d, J=9.7 Hz, 2H), 7.24 (d, J=7.8 Hz, 1H), 6.96 (dd, J=21.3, 8.1 Hz, 3H), 6.81 (d, J=7.9 Hz, 1H), 6.62 (t, J=7.6 Hz, 1H), 4.98 (s, 2H), 3.71 (t, J=4.7 Hz, 4H), 2.99 (t, J=4.7 Hz, 4H). MS m/z 506.4 [M+H]+.
-
- Compound 12b was prepared by compound 12a according to the synthesis of compound 1b. The synthesis method of 12 from 11e and 12b by a multi-step reaction can refer to the synthesis of compound 10. 1H NMR (400 MHz, DMSO-d6): δ 10.47 (s, 1H), 8.82 (s, 1H), 8.19 (s, 1H), 8.03-8.09 (m, 5H), 7.70-7.72 (d, J=8.2 Hz, 1H), 7.50-7.53 (d, J=15.8 Hz, 1H), 7.33 (br, 2H), 6.55-6.58 (d, J=15.8 Hz, 1H), 3.88 (t, 4H), 3.29 (t, 4H). MS m/z 457.6 [M+H]+.
-
- 11e (3.0 g, 8.1 mmol), 11h (2.4 g, 9.6 mmol), 1,4-dioxane (30 ml), water (6.1 ml), potassium carbonate (2.2 g, 16.1 mmol) and Pd(dppf) Cl2.DCM (164 mg, 0.2 mmol) were added successively into a 100 ml three-necked flask. The system was replaced with nitrogen gas for three times under stirring, and then warmed to 90° C. to reflux for 16 hours. After filtration, the filter cake was soaked with methanol (20 ml×3) and discarded. The combined organic phase was concentrated to dry under reduced pressure, and the resulting solid was washed pulped with n-hexane (3 mL)-dichloromethane (12 ml) under 21° C. for 2 h. After filtration, the filter cake was washed with dichloromethane (12.3 mL) and dried in a blast oven for 16 hours under 40° C. to give light green solid compound 13a (3.3 g, purity 94.2%, yield 98.8%). 1H NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.56 (s, 1H), 8.46 (t, J=1.8 Hz, 1H), 8.08-7.99 (m, 3H), 7.97-7.80 (m, 4H), 7.61 (s, 1H), 7.36 (t, J=7.6 Hz, 1H), 7.27-7.19 (m, 2H), 6.97 (d, J=8.9 Hz, 2H), 3.75 (t, J=4.7 Hz, 4H), 3.08 (t, J=4.8 Hz, 4H).
- 13a (0.2 g, 0.5 mmol) was dissolved in dichloromethane (2.3 ml), and 1-hydroxybenzotriazole (71 mg, 0.5 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (138 mg, 0.7 mmol) and 4-dimethylamine pyridine (118 mg, 0.9 mmol) were added sequentially under stirring. The system was stirred at 25° C. to react for 0.5 hours. 10b (114 mg, 0.5 mmol) was added and the reaction was stirred at 25° C. to react for 16 h. The reaction was concentrated under reduced pressure to dryness, and purified the crude by silica gel column (methanol/dichloromethane=1/200 to 1/75) to give yellow solid 13b (192 mg, purity 78.5%, yield 62.9%).
- 13b (190 mg, 0.3 mmol) was dissolved in methanol (2.1 mL) and trifluoroacetic acid (216 mg, 1.5 mmol) was added dropwise at 25° C. After the dropwise addition was completed, the system was stirred for 0.5 hours, and then warmed to 40° C. and stirred to react for 20 hours. The reaction solution was cooled to 25° C. After filtration, the filter cake was pulped with isopropanol (3.1 mL) at 85° C. for 1 hour. The system was slowly nature cooled to 25° C. by constant stirring and filtered. The filter cake was dried in a vacuum oven at 40° C. for 16 hours to give a yellow solid 13 (30 mg, purity 90.1%, yield 18.2%). 1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, 1H), 10.68 (s, 1H), 9.65 (s, 1H), 8.78 (s, 1H), 8.61 (s, 1H), 8.22 (d, J=7.5 Hz, 1H), 8.12-7.60 (m, 11H), 6.96 (t, J=9.8 Hz, 2H), 3.70 (d, J=9.1 Hz, 4H), 2.98 (t, J=4.4 Hz, 4H). MS m/z 550.5 [M+H]+.
-
- 6-Bromocarbazole (6.0 g, 30.6 mmol), methyl 7-bromoheptanoate (10.8 g, 45.9 mmol), N,N-dimethylformamide (60.5 ml) and potassium carbonate (12.7 g, 91.8 mmol) were sequentially added to a 100 ml three-necked flask. The system was heated to 100° C. and stirred to react for 6.5 hours. The reaction was monitored by thin layer chromatography (ethyl acetate/n-hexane=1/1, UV=254 nm) until the starting material disappeared. Water (120 ml) was added after the reaction mixture was cooled to 17° C., and extracted with ethyl acetate (50 ml×3). The combined organic phases were washed with saturated aqueous solution of sodium chloride (120 mL×3) and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (ethyl acetate/n-hexane=1/20 to 1/5) to give orange-red solid 14a (4.6 g, purity 92.4%, yield 42.7%). The synthesis of the compound 14 by a multi-step reaction from the compound 14a can be carried out by referring to the synthesis steps of the above compounds 10, 11, and 12.
- Compound 14: bright yellow solid (purity 91.0%). 1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 9.66 (s, 1H), 8.76 (s, 1H), 8.27 (s, 1H), 8.13-7.94 (m, 4H), 7.90-7.69 (m, 3H), 7.08 (d, J=8.5 Hz, 2H), 4.46 (t, J=6.9 Hz, 2H), 3.80 (t, J=4.7 Hz, 4H), 3.16 (t, J=4.7 Hz, 4H), 1.90 (t, J=7.2 Hz, 4H), 1.44 (q, J=7.2 Hz, 2H), 1.36-1.21 (m, 4H). MS m/z 555.6 [M+H]+.
-
- The synthesis procedure of the compound 10b was referred, compound 13 (0.7 g) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine was reacted at 21° C. for 5 hours to obtain a pale yellow solid compound 15a (0.6 g, purity 93.6%, yield 62.7%). MS m/z 515.4 [M+H]+.
- The synthesis process of compound 10 was referred. 15a (150 mg) and trifluoroacetic acid were reacted at 21° C. for 24 hours to give bright yellow solid 15 (30 mg, purity 95.9%, yield 23.9%). 1H NMR (400 MHz, DMSO-d6) δ 11.29 (s, 1H), 9.52 (s, 1H), 9.09 (s, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.38 (s, 1H), 8.14 (d, J=7.6 Hz, 1H), 8.01 (d, J=8.6 Hz, 3H), 7.75-7.53 (m, 3H), 6.97 (d, J=8.6 Hz, 2H), 3.76 (t, J=4.7 Hz, 4H), 3.09 (t, J=4.8 Hz, 4H). MS m/z 431.3 [M+H]+.
-
- The synthesis procedure of the compound 10b was referred, 13a (200 mg) and O-methylhydroxylamine hydrochloride was reacted to afford white solid compound 16 (46 mg, purity 96.9%, yield 21.4%). 1H NMR (400 MHz, DMSO-d6) δ 11.82 (s, 1H), 9.53 (s, 1H). 8.66 (s, 1H), 8.37 (t, J=1.8 Hz, 1H), 8.17 (dt, J=7.8, 1.5 Hz, 1H), 8.05-7.97 (m, 3H), 7.72 (dt, J=7.8, 1.3 Hz, 1H), 7.65 (d, J=1.1 Hz, 1H), 7.59 (t, J=7.7 Hz, 1H), 7.01-6.93 (m, 2H). 3.75 (d, J=4.9 Hz, 7H), 3.12-3.05 (m, 4H). MS m/z 445.6 [M+H]+.
-
- Compound 17 was prepared from compound 13a by a multi-step reaction. The specific experimental procedure was according to the synthesis of the above compound 10-13. Compound 17: 1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 9.52 (s, 1H), 8.66 (s, 1H), 8.56 (t, J=5.6 Hz, 1H), 8.42 (t, J=1.8 Hz, 1H), 8.14 (dt, J=7.8, 1.5 Hz, 1H), 8.08-7.98 (m, 3H), 7.81 (dt, J=7.8, 1.5 Hz, 1H), 7.65 (d, J=1.1 Hz, 1H), 7.57 (t, J=7.8 Hz, 1H), 7.02-6.94 (m, 2H), 3.75 (dd, J=5.9, 3.6 Hz, 4H), 3.13-3.04 (m, 4H). MS m/z 559.0 [M+H]+.
-
- Compound 18 was prepared by a multi-step reaction from compound 18a and compound 10c. The specific experimental procedure was according to the synthesis of the above compound 10-13. Compound 18: 1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 9.37 (d, J=14.6 Hz, 1H), 8.66 (s, 1H), 8.08 (d, J=26.4 Hz, 1H), 7.98-7.85 (m, 3H), 7.58 (d, J=10.2 Hz, 1H), 6.94 (d, J=8.8 Hz, 2H), 6.78 (d, J=17.7 Hz, 1H), 4.37 (s, 2H), 3.74 (dd, J=6.0, 3.5 Hz, 4H), 3.61 (dt, J=8.5, 5.8 Hz, 3H), 3.07 (tt, J=5.1, 2.2 Hz, 6H), 2.47-2.23 (m, 4H), 1.97 (d, J=6.8 Hz, 2H), 1.53 (dd, J=7.0, 3.6 Hz, 4H), 1.24 (t, J=5.9 Hz, 7H). MS m/z 520.5 [M+H]+.
-
- According to the synthetic procedure of the compound 13, 17c (100 mg) and compound 19a were reacted at room temperature for 16 hours, followed by purification to obtain bright yellow solid 19 (50 mg, purity 96.4%, yield 42.9%). 1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.08 (s, 1H), 8.64 (s, 1H), 8.54 (t, J=5.6 Hz, 1H), 8.41 (t, J=1.8 Hz, 1H), 8.16-8.09 (m, 1H), 8.05-7.97 (m, 3H), 7.81 (dt, J=7.8, 1.4 Hz, 1H), 7.66-7.51 (m, 2H), 7.15 (dd, J=7.9, 1.5 Hz, 1H), 7.01-6.83 (m, 3H), 6.70 (dd, J=7.9, 1.5 Hz, 1H), 6.56-6.48 (m, 1H), 4.80 (s, 2H), 3.75 (dd, J=6.0, 3.7 Hz, 4H), 3.12-3.03 (m, 4H), 2.32 (t, J=7.4 Hz, 2H), 1.60 (d, J=10.7 Hz, 4H), 1.46-1.19 (m, 6H). MS m/z 633.9 [M+H]+.
-
- 20a (2.1 g, 9.9 mmol), 17a (2.3 g, 11.9 mmol), potassium carbonate (4.1 g, 29.7 mmol), potassium iodide (146 mg, 1.0 mmol), iodine cuprous (0.4 g, 2.0 mmol), L-valine (144 mg, 1.0 mmol) and N,N-dimethylacetamide (20.2 ml) were added to a 50 ml three-necked flask successively. The system was replaced with nitrogen for three times, and stirred to react at 90° C. for 24 hours. Water (40 ml) was added, and the mixture was extracted with ethyl acetate (30 ml×3). The combined organic phase was washed with saturated brine (60 mL), dried, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:ethyl acetate=10:1) to give yellow solid compound 20b (1.0 g, purity 91.8%, yield 36.1%). MS m/z 280.9 [M+H]+.
- 20b (0.6 g, 2.1 mmol), sodium hydride (0.1 g, 3.2 mmol), N,N-dimethylformamide (6.1 ml) were added to 50 ml three-necked flask, and the system was replaced with nitrogen for three times. The reaction was stirred for 1 hour after cooled to 0° C., and then with methyl iodide (0.9 g, 6.4 mmol) was added and stirred for 1 hour. Ethyl acetate (35.5 ml) was added to the reaction mixture, and the organic phase was washed with saturated brine (40.5 ml). The organic phase was concentrated to dryness and purified by silica gel column chromatography (hexane:ethyl acetate=10:1) to provide bright yellow oil 20c (1 g, yield 92.1%). MS m/z 295.4 [M+H]+.
- 20c (0.4 g, 1.4 mmol), zinc powder (0.5 g, 7.1 mmol), ammonium chloride (0.7 g, 14.3 mmol), ethanol (4.2 ml) and water (0.8 ml) were added to a 25 ml three-necked flask. The system was replaced with N2 for three times, and heated to 60° C. and stirred to react for 16 hours. The reaction solution was suction filtered, and the filtrate was concentrated to remove the ethanol, and extracted with ethyl acetate (10 mL) for three times. The combined organic phases were concentrated to give compound 20d (480 mg, 83.9% purity). MS m/z 265.2 [M+H]+.
- 20d (0.4 g, 1.5 mmol), 1a (0.4 g, 1.5 mmol), N,N-diisopropylethylamine (0.6 g, 4.5 mmol), isopropanol (4.1 mL) were added into reaction flask. The system was replaced with nitrogen for three times, warmed to 90° C. and stirred for 16 hours. The reaction mixture was concentrated to dry and purified by silica gel column chromatography (hexane:ethyl acetate=8:1) to give compound 20e (0.6 g, purity 88.6%, and the yield was 82.6%). MS m/z 460.3 [M+H]+.
- 20e (0.7 g, 1.5 mmol), 20f (1.6 g, 4.6 mmol), potassium carbonate (0.4 g, 3.1 mmol), Pd(dppf) Cl2 (125 mg, 0.2 mmol), 1,4-dioxane (7.1 ml) and water (1.4 ml) were added to pressure-resistant bottle. After the system was replaced with nitrogen for 3 times, the system was warmed to 110° C. and stirred to react for 16 hours. The reaction solution was filtered, concentrated to dry and purified by silica gel column chromatography (n-hexane:ethyl acetate=2:1) to gave compound 20g (0.5 g, purity 99.8%, yield 63.4%). MS m/z 498.6 [M-Boc+H]+.
- 20g (0.5 g, 0.9 mmol), sodium hydroxide (0.2 g, 4.8 mmol), methanol (48.2 ml) and water (10.2 ml) were successively added into a reaction flask, and the mixture was warmed to 40° C. and stirred to react for 16 hours. The reaction mixture was adjusted to pH 3-4 with dilute hydrochloric acid and then concentrated to dry to give Compound 20h (0.3 g, purity 100%). MS m/z 484.4 [M+H]+.
- 20h (0.6 g, 1.3 mmol), HOBT (0.2 g, 1.4 mmol), EDCI (0.3 g, 1.7 mmol), N,N-diisopropylethylamine (0.3 g, 2.6 mmol), H2N-OTHP (0.2 g, 1.5 mmol), and N,N-dimethylacetamide (15.2 ml) were added successively into a reaction flask and stirred at room temperature for 6 hours. Water (30.5 ml) was added, and the mixture was extracted with ethyl acetate (150 mL×3). The combined organic phase was washed with saturated sodium chloride (50.5 ml), and the combined organic phase was concentrated to dry and purified by silica gel column chromatography (methanol:dichloromethane=1:50). The solid compound 20i (0.4 g, purity 98.3% yield 56.1%) was obtained. MS m/z 583.7 [M+H]+.
- 20i (0.2 g, 0.3 mmol), methanol (4.1 ml) and trifluoroacetic acid (0.5 g, 3.4 mmol) were successively added into a reaction flask and stirred at room temperature for 24 hours. The reaction solution was filtered, and the filter cake was dried in vacuo to provide compound 20 (50 mg, purity 99.5%, yield 29.2%). 1H NMR (400 MHz, DMSO-d6) δ 10.31 (br, 1H), 9.85 (br, 1H), 8.74 (s, 1H), 8.23 (br, 2H), 8.15 (s, 1H), 8.11 (d, J=0.9, 1H), 8.05 (d, J=0.9, 2H), 7.85-7.87 (d, J=8.4 Hz, 1H), 7.74 (d, J=1.3 Hz, 1H), 7.72 (d, J=2.7 Hz, 1H), 7.31 (br, 2H), 3.45 (t, 2H), 3.11 (s, 3H), 1.92 (t, J=7.2 Hz, 2H), 1.44-1.47 (m, 4H), 1.22-1.26 (m, 4H). MS m/z 499.9 [M+H]+.
-
- 21b (1.4 g, 9.6 mmol) was dissolved in dichloromethane (20.5 mL), and 1-hydroxybenzotriazole (1.4 g, 10.6 mmol), EDCI (2.4 g, 12.5 mmol), 4-dimethylaminopyridine (118 mg, 0.9 mmol), N,N-diisopropylethylamine (3.7 g, 28.9 mmol) were successively added to the system. The reaction mixture was stirred at room temperature for half an hour and then 21a (2.0 g, 9.6 mmol) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was washed with water (10.5 ml). After concentrated under reduced pressure, the organic phase was purified by silica gel column chromatography (n-hexane/ethyl acetate=10/1 mixed solvent elution) to give a bright yellow solid Compound 21c (1.7 g, yield 52.6%).
- 21c (1.7 g, 5.1 mmol) was placed in a 100 ml three-necked flask, and methanol (17.5 ml), ammonium chloride (2.7 g, 50.7 mmol), zinc powder (1.6 g, 25.4 mmol), water (6.2 ml) were sequentially added into the reaction flask. The reaction system was replaced with nitrogen for three times, heated to 60° C., and stirred for 4.5 hours. The reaction liquid was suction filtered to remove solid impurities, and the reaction liquid was concentrated to remove methanol to give crude product 21d (1.6 g).
- 21d (1.6 g, 5.2 mmol), 1a (1.4 g, 5.2 mmol), N,N-diisopropylethylamine (2.0 g, 15.7 mmol), isopropanol (16.2 mL) were added successively to 50 mL three-necked flask. The reaction system was replaced with nitrogen for three times, warmed to 90° C., and stirred to react for 5 hours. The reaction mixture was concentrated and purified by silica gel column chromatography (hexane/ethyl acetate=20/1) to give a crude product 21e (1.6 g, 60.5% yield).
- 21e (0.5 g, 1.0 mmol), 20f (1.0 g, 3.0 mmol), Pd(dppf)Cl2-DCM (82 mg, 0.1 mmol), potassium carbonate (276 mg, 2.0 mmol), water (1.1 ml) and 1,4-dioxane (5.2 ml) were successively added to sealed pot, and was blown with nitrogen. After sealing, the reaction system was heated to 110° C. and stirred to react for 6 hours. The reaction solution was suction filtered, and the crude product was purified by silica gel column chromatography (hexane/ethyl acetate=3/1) to afford compound 21f (450 mg, purity 90.9%, yield 83.6%).
- 21f (0.4 g, 0.8 mmol) was suspended in water (4.5 ml), and sodium hydroxide (0.1 g, 2.5 mmol) was added. The mixture was warmed to 100° C., and the reaction was stirred for 1 hour. After cooled to room temperature, the pH of reaction mixture was adjusted to about 2 to 3 with 37% hydrochloric acid, and the reaction mixture was concentrated to dry to afford crude product 21g (0.6 g, purity 83.8%).
- 21g (0.6 g, 0.8 mmol) was dissolved in dichloromethane (60.5 mL) and N,N-dimethylacetamide (0.3 g, 2.5 mmol), 1-hydroxybenzene triazole (124 mg, 0.9 mmol), EDCI (208 mg, 1.1 mmol) were added dropwise successively under stirring. The mixture was stirred to react at room temperature for 0.5 h, then H2N-OTHP (108 mg, 0.9 mmol) was added and the mixture was stirred at room temperature overnight. Water (30.5 ml) was added to the reaction mixture, and extracted with dichloromethane (20.5 ml). The organic phase was concentrated and purified by silica gel column chromatographe to give yellow-green solid 21h (160 mg, 81.0% purity, 30.6% yield).
- 21h (160 mg, 0.2 mmol) was dissolved in methanol (3.1 mL), trifluoroacetic acid (185 mg, 1.3 mmol) was added under stirring, and reacted at room temperature for 3.5 hours and then at 40° C. for 4.5 hours, then heated to 60° C. to react for 15 minutes. After the reaction mixture was cooled to room temperature, 70 mg of filter cake was obtained. The filter cake was dissolved in N,N-dimethylformamide (1.1 ml), and purified by preparative liquid phase reverse-phase column chromatography to obtain compound 21 (20 mg, purity 97.8%, yield 14.5%). 1H NMR (400 MHz, DMSO-d6) δ 10.35 (br, 1H), 9.61 (br, 1H), 8.71 (s, 1H), 8.18 (s, 1H), 8.09 (d, J=0.9 Hz, 1H), 8.02-8.04 (m, 3H), 7.83-7.86 (d, J=8.5, 1H), 7.73 (d, J=0.9 Hz, 1H), 7.71 (d, J=1.4 Hz, 1H), 7.09 (d, J=9.1 Hz, 2H), 3.63 (4H), 3.13 (4H), 2.36 (t, J=7.4 Hz, 2H), 2.01 (t, J=7.4 Hz, 2H), 1.75 (m, 2H).
-
- 22a (4.0 g, 19.8 mmol) was dissolved in N,N-dimethylacetamide (30.5 mL), then 22b (2.2 g, 29.7 mmol), potassium carbonate (8.2 g, 59.4 mmol), potassium iodide (329 mg, 1.9 mmol), cuprous iodide (377 mg, 1.9 mmol), and L-valine (228 mg, 1.9 mmol) were added successively. The reaction system was replaced with nitrogen for three times, and heated to 120° C. and stirred overnight. Water (160 ml) was added to the reaction mixture and extracted with ethyl acetate (80 mL×3), the extracted organic phase was concentrated, and separated by silica gel column chromatography (hexane/ethyl acetate=10/1) to give 22c (2.9 g, purity 99.9%, yield 76.4%).
- 22c (500 mg, 2.5 mmol) and 22d (5.0 ml) were added to a tank reactor, and potassium hydroxide (50 mg, 0.7 mmol) was added. The reaction system was blown with nitrogen, and heated to 120° C. and stirred overnight. The reaction solution was concentrated to remove the remaining 22d, and purified by preparative thin-layer chromatography (developing solvent:n-hexane/ethyl acetate=2/1, UV=254 nm, Rf=0.6) to provide 22e (400 mg, purity 73.1%, yield 52.9%).
- 22e (400 mg, 1.3 mmol), zinc powder (441 mg, 6.7 mmol), ammonium chloride (722 mg, 13.5 mmol), methanol (4.1 ml) and water (1.1) were added to a 25 ml three-necked flask. The reaction system was replaced with nitrogen for three times, then heated to 40° C. to react for 3 hours, and warmed to 50° C. to react for 40 minutes, then warmed to 60° C. to react for 2.5 hours. The reaction solution was suction filtered, and the filtered cake was concentrated to remove methanol and water. Water (30.5 ml) was added and extracted with ethyl acetate (30 ml×3), and the combined organic phases were concentrated under reduced pressure to provide crude product 22f (320 mg, yield 89.0%).
- 22f (320 mg, 0.9 mmol), 1a (266 mg, 0.9 mmol), N,N-diisopropylethylamine (373 mg, 2.8 mmol), and isopropanol (3.1 mL) were added successively to 50 mL three-necked flask. The reaction system was replaced with nitrogen for three times, warmed to 90° C., and stirred to react for 5 hours. The reaction solution was concentrated and purified by preparative thin-layer chromatography (developing solvent:n-hexane/ethyl acetate=1/1, UV=254 nm, Rf=0.4) to provide compound 22e (250 mg, purity 97.6%, yield 56.4%).
- 22g (50 mg, 0.1 mmol), 20f (112 mg, 0.3 mmol), Pd(dppf)Cl2-DCM (9 mg, 0.01 mmol), potassium carbonate (30 mg, 0.2 mmol), water (0.4 ml) and 1,4-dioxane (2.1 ml) were successively added to sealed pot, and was blown with nitrogen. After sealing, the reaction system was heated to 110° C. and stirred to react for 6 hours. The reaction solution was suction filtered, and the crude product obtained by concentrating the filtrate was purified by preparative thin-layer chromatography (developing solvent=dichloromethane/methanol=20/1, UV=254 nm, Rf=0.4, Rf=0.1) to provide 22i (24 mg, purity 90.9%).
- 22i (24 mg, 0.05 mmol) was dissolved in dichloromethane (5.1 mL), and N,N-dimethylacetamide (13 mg, 0.1 mmol), 1-hydroxybenzene triazole (8 mg, 0.05 mmol), EDCI (13 mg, 0.06 mmol) were added dropwise successively under stirring. The mixture was stirred to react at room temperature for 0.5 h, then H2N-OTHP (7 mg, 0.06 mmol) was added and the mixture was stirred at room temperature overnight. Water (10 ml) and dichloromethane (10 ml) were added to the reaction mixture, and the organic phase was concentrated and purified by preparative thin-layer chromatography (developing solvent:n-hexane/ethyl acetate=1/1, UV=254 nm, Rf=0.4) to provide product 22j (14 mg, purity 97.9%, yield 48.2%).
- 22j (14 mg, 0.02 mmol) was dissolved in methanol (3.1 mL), and trifluoroacetic acid (14 mg, 0.1 mmol) was added under stirring, and stirred at room temperature overnight, then warmed to 40° C. to react for 5.5 hours. The reaction solution was filtered, and the filter cake was dried overnight at 30° C. in a vacuum oven to give pale yellow 22 (1.9 mg, purity 95.4%, yield 14.5%). MS m/z 487.1 [M+H]+.
-
- 22a (5.1 g, 31.7 mmol) and ethylenediamine (20.1 ml) were added to a reaction flask, and the air in the system was replaced with N2 gas for three times, and then (the mixture) heated to 120° C. to react for 2 hours. The raw material was detected to been consumed by thin layer chromatography (ethyl acetate/n-hexane=1/3). The reaction was cooled to room temperature and concentrated under reduced pressure. Water (25 mL) was then added and pulped at 100° C. for 1 hour. After filtration, the filter cake was transferred to a watch glass and placed in a forced air oven at 60° C. for drying. After drying, a bright yellow solid 23a (5.5 g, yield 95.7%) was obtained.
- 23a (3.6 g, 26.1 mmol), 23b (3.4 g, 26.0 mmol), and triethylamine (4.0 g, 52.1 mmol) were dissolved in methanol (50.5 ml) and reacted at room temperature for 16 hours. The reaction was monitored by thin layer chromatography (methanol/dichloromethane=1/5) until the starting material point (Rf=0.6) disappeared and a new spot was formed (Rf=0.8). The reaction mixture was concentrated under reduced pressure to give a bright yellow solid compound 23c (4.6 g, purity 86.2%, yield 55.6%).
- 23c (4.6 g, 14.5 mmol) was dissolved in N,N-dimethylformamide (50 mL) to reduce the system temperature to below 0° C. Sodium hydride (1.7 g, 43.5 mmol) was slowly added portionwise, during which the temperature was kept below 0° C., and then stirred for 1 hour to react after the addition. Methyl iodide (12.5 g, 87.0 mmol) was added slowly, and the reaction was carried out at 0° C. for 2 hours. The raw material was detected to been consumed by thin layer chromatography (ethyl acetate/n-hexane=1/1). Water (50.1 ml) was added to the reaction mixture, and extracted with ethyl acetate (50 mL×3). The combined organic phase was dried, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:ethyl acetate=8:1 solvent mixture elution) to give yellow solid compound 23d (1.9 g, purity 88.5%, yield 41.5%). MS m/z 346.3 [M+H]+.
- 23d (1.9 g, 5.5 mmol), ammonium chloride (2.9 g, 55.0 mmol), zinc powder (1.8 g, 27.5 mmol), and water (4.1 ml) were dissolved in methanol (19.2 ml). The reaction system was replaced with nitrogen for three times and heated to 50° C. to react for 4 hours. The reaction mixture was filtered after thin layer chromatography (ethyl acetate/n-hexane=1/1) monitor showed that the starting material was consumed. The filtrate was washed with methanol (20.2 ml), and the organic filtrate was combined and concentrated to dryness to give solid compound 23e (810 mg, yield 46.6%).
- 23e (810 mg, 2.5 mmol), 1a (712 mg, 2.5 mmol), N,N-diisopropylethylamine (996 mg, 7.7 mmol) were dissolved in isopropyl alcohol (8.1 mL). The reaction system was replaced with nitrogen for three times, and warmed to 90° C. and stirred to react overnight. The raw material was detected to been consumed by thin layer chromatography (ethyl acetate/n-hexane=1/1). The reaction was concentrated under reduced pressure, the obtained crude product was purified by silica gel column chromatography (hexane/ethyl acetate=5/1 mixed solvent elution) to provide yellow solid compound 23f (908 mg, purity 96.0%, yield 69.1%).
- 23f (300 mg, 0.6 mmol), C62-9 (606 mg, 1.7 mmol), sodium hydroxide (188 mg, 4.7 mmol), Pd(dppf)Cl2.DCM (144 mg, 0.2 mmol) were dissolved in 1,4-dioxane (3.2 ml). The reaction system was replaced with nitrogen for three times, and the mixture was warmed to 110° C. and stirred to react overnight. The reactant was cooled to room temperature, and dilute hydrochloric acid was added to the reaction mixture to adjust the pH to 4 to 5. The reaction mixture became cloudy and yellow solid was formed. Ethyl acetate (10 ml) was added to the mixture and stirred for 0.5 hr. Filtered to give a crude yellow solid, and purified by preparative thin layer chromatography to provide yellow solid 23g (270 mg, yield 86.1%). MS m/z 535.6 [M+H]+.
- 23g (150 mg, 0.3 mmol), 1-hydroxybenzotriazole (42 mg, 0.3 mmol), carbodiimide hydrochloride (70 mg, 0.4 mmol), N,N-diisopropyl ethylamine (73 mg, 0.5 mmol) were dissolved in N,N-dimethylformamide (1.5 ml), stirred at room temperature for 30 min, and NH2 OTHP (45.7 mg, 0.4 mmol) was added and stirred to react overnight. The reaction was cooled to room temperature, and the crude product was purified by preparative thin-layer chromatography to provide green solid compound 23h (62 mg, 88.6% purity, 41.4% yield). MS m/z 634.7 [M-Boc+H]+.
- 23h (62 mg, 0.1 mmol) was dissolved in methanol (15.2 ml), trifluoroacetic acid (177 mg, 1.5 mmol) was added, and the system was warmed to 60° C. to react for 4 hours. The insolubles appeared in the reaction mixture was the product. Thin layer chromatography (dichloromethane:methanol=1:10) monitored that the starting material was consumed. After filtration, the filter cake was dried in a vacuum oven at 40° C. to obtain bright yellow solid 23 (20 mg, purity 95.4%, yield 35.5%). 1H NMR (400 MHz, DMSO-d6) δ 13.19 (s, 1H), 11.06 (s, 1H), 9.45 (s, 1H), 8.68 (d, J=14.9 Hz, 3H), 8.16 (s, 1H), 8.10 (s, 1H), 8.01 (s, 1H), 7.95 (d, J=8.5 Hz, 2H), 7.85 (d, J=8.5 Hz, 1H), 7.75-7.68 (m, 2H), 6.88 (d, J=8.1 Hz, 2H), 3.82 (t, J=6.7 Hz, 2H), 3.60 (t, J=6.7 Hz, 2H), 2.97 (s, 3H). MS m/z 550.5 [M+H]+.
- 1. Syk Kinase Activity Inhibitory Experiment
- Measure of SYK protein kinase activity was carried out by using the Caliper mobility shift assay. The compound was dissolved with DMSO and diluted with kinase buffer (20 mM HEPES pH 7.5, 0.01% Triton X-100, 5 mM MgCl2, 1 mM MnCl2, 2 mM DTT), and 5 μl of 5 times the final concentration of the compounds (10% DMSO) were added to 384 well plate. 10 μl of 2.5 fold enzyme (with SYK) solution was added and incubated at room temperature for 10 minutes, then 10 μl of 2.5 fold substrate (Peptide FAM-P22) and ATP) solution was added. The mixture was incubated for 30 minutes under 28° C., and 25 μl of stop buffer (100 mM HEPES pH 7.5, 0.015% Brij-35, 0.2% Coating Reagent #3, 50 mM EDTA) was added to terminate the reaction. Conversion rate data was read by Caliper EZ Reader II (Caliper Life Sciences). Conversion rate was converted to inhibition rate data (% inhibition rate=(max−conversion rate)/(max−min)*100). The max refers to the conversion rate of the DMSO control, and min refers to the conversion rate of the enzyme-free control. The curve was drawn with the compound concentration and inhibition rate as the horizontal and vertical coordinates, and the curve was fitted with the XLFit excel add-in version 4.3.1 Software, and IC50 was calculated.
- The results indicate that the IC50 of majority of the tested compounds of the present invention was 10-1000 nM, and the IC50 of preferred compound was lower than 20 nM. The activities of some representative compounds are shown in Table 1.
-
TABLE 1 Inhibition of Syk kinase activity Compound Syk (IC50, nM) 1R <10 2R <10 3R <500 4R <10 5R <10 6 <10 7 <10 8R <10 9R <100 11 <500 12 <100 13 <100 14 <500 17 <1000 18 <500 19 <1000 20 <50 21 <10 22 <50 23 <50 - 2. HDAC-1 and HDAC-6 Activity Inhibition Experiment
- HDAC activity was measured by the Synergy MX Multi-Function Microplate Reader. The compounds were dissolved with DMSO, and transferred to a 384 well test plate using an Echo non-contact nanoscale sonic pipetting system. 15 μl of enzyme (HDAC1/HDAC6, respectively) solvent was added, and incubated at room temperature for 15 minutes, then 10 μl of substrate (trypsin and Ac-peptide) solution was added. Fluorescence intensity signal was read directly on Synergy MX (fluorescence excitation 355 nm, emission fluorescence 460 nm) after cultivated at room temperature for 60 minutes. Fluorescence intensity signal was convented into inhibition rate data (% inhibition rate=(max−fluorescence intensity)/(max−min)*100). The max refers to the fluorescence intensity of the DMSO control, and min refers to the fluorescence intensity of the enzyme-free control. The curve was drawn with the compound concentration and inhibition rate as the horizontal and vertical coordinates, and the curve was fitted with the GraphPad Prism V5.0 Software, and IC50 was calculated.
-
TABLE 2 HDAC activity inhibition Compound HDAC1 (IC50, nM) HDAC6 (IC50, nM) 6 <1000 <50 7 <30 <30 10 <2000 12 <200 13 <200 14 <20 17 <50 18 <100 19 <500 20 <20 21 <100 22 <500 23 <30 - All literatures mentioned in the present application are incorporated herein by reference, as though each one is individually incorporated by reference. Additionally, it should be understood that after reading the above content, those skilled in the art can make various changes and modifications to the present invention. These equivalents also fall within the scope defined by the appended claims.
Claims (8)
1. A compound of the following formula (I), or the optical isomers, pharmaceutically acceptable salts thereof:
wherein in the formula (I),
R1 is aryl, heteroaryl or 6-membered monocyclic heterocyclyl (including saturated and unsaturated); aryl, heteroaryl or monocyclic heterocyclyl herein may be optionally and independently substituted by 1-3 substituents each independently selected from the group consisting of: halogen, C1-4 alkyl, C1-4 halogenated alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, NO2, OR8, SR8, NR8R9, C(O)R8, C(O)OR8, C(O)NR8R9, S(O)2R8 and R7;
R2, R3 and R4 are hydrogen;
U is NR5; where R5 is hydrogen;
A is the group of formula (III):
wherein:
“*” indicates a chiral center;
each X is independently hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, OR8, SR8, NR8R9, C(O)R8, C(O)OR8, C(O)NR8R9, or S(O)2R8;
R7 is hydrogen, —(CH2)p—V—(CH2)qC(O)NH(OH), —V1—(CH2)p—V2—V—(CH2)qC(O)NH(OH), C(O)NH(OCH3),
J is O;
G is NR10;
n is 0, 1, 2, or 3;
each R6 is hydrogen, or two R6 connecting to the same carbon atom form carbonyl group (═O);
R8 and R9 are each independently hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, or heteroaryl; or R8 and R9 together with the nitrogen atom to which they are attached form a 3- to 9-metacyclic ring comprising 1-2 N atom and 0, 1 or 2 heteroatoms selected from O or S;
R10 is C2-8 alkyl, C1-8 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 3- to 12-membered heterocyclyl (optionally comprising 1-2 heteroatoms selected from O, N, or S), aryl, heteroaryl, C(O)R8, C(O)OR8, C(O)NR8R9, S(O)2R8 or (CH2)p—V—(CH2)qC(O)NH(OH), wherein R8 is not hydrogen, and the R8 in C(O)R8 is not methyl;
V is a divalent group, each of p and q is independently an integer from 0 to 10, and the V is selected from the group consisting of bond, O, S, NR11, OC(O), OC(O)O, NHC(O), NHC(O)NH, NHC(O)O, OC(O)NH, NHS(O)2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)2NH, or NHS(O)2NH, CH═CH, C≡C, CR12R13, C3-8 cycloalkyl, 3- to 12-member heterocyclyl, aryl or heteroaryl,
with the prerequisite that V, p and q together form a chemically stable group;
V1 and V2 are divalent groups selected from the group consisting of bond, O, S, NR11, and C(O)NH, with the prerequisite that the group formed by V, V1, V2, p and q is chemically stable group;
R11 is hydrogen, C1-4 alkyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, C(O)R8 or S(O)2R8;
R12 and R13 are each independently hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, 3- to 8-membered heterocyclic, OR8, SR8, NR8R9, CN, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8, NR8C(O)R9, or S(O)2R8, or R12 and R13 together with the carbon atoms to which they are attached form 3-8 membered cyclic structure containing 0, 1 or 2 heteroatoms selected from N, O, or S;
with the proviso that when R1 does not comprise structural unit
then A is of formula (IIIa),
wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally and independently substituted by 1-3 substituents each independently selected from the group consisting of halogen, C1-4 alkyl, C1-4 halogenated alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-heterocyclyl, aryl, heteroaryl, CN, NO2, OR8, SR8, NR8R9, C(O)R8, C(O)OR8, C(O)NR8R9 or S(O)2R8;
unless otherwise specified, the above aryl group is an aryl group having 6 to 12 carbon atoms; and the heteroaryl group is a 5- to 15-membered heteroaryl group.
3. The compound of claim 1 , or the optical isomers, pharmaceutically acceptable salts thereof, wherein the formula (III) is a structure selected from group consisting of:
wherein R10 is C2-8 alkyl, C1-8 halogenated alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 6-membered heterocyclyl (optionally comprising 1-2 heteroatoms selected from O, N, S), aryl, heteroaryl, C(O)R8, C(O)OR8, C(O)NR8R9, S(O)2R8, wherein R8 is selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl; wherein R8 in C(O)R8 is other than methyl; or R8 and R9 together with the nitrogen atom to which they are attached form a 3- to 9-membered ring comprising 1-2 N atom and 0, 1 or 2 hetero atoms selected from O or S.
4. The compound of claim 1 , or the optical isomers, pharmaceutically acceptable salts thereof, wherein the formula (I) is selected from group consisting of:
wherein R10 is C2-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, unsubstituted or C1-4 alkyl substituted 6-membered heterocyclyl (optionally containing 1-2 heteroatoms selected from O, or N), C(O)R8, or S(O)2R8; R8 is C1-4 alkyl or C1-4 haloalkyl; wherein the R8 in C(O)R8 is other than methyl.
6. A method for treating a disease associated with Syk and/or HDAC kinase activity or expression amount, comprising the step: administrating the compound (I) of claim 1 , or the optical isomers, pharmaceutically acceptable salts thereof to a subject in need thereof, wherein the disease is selected from the group consisting of lymphoma, lymphocytic leukemia, cutaneous T-cell lymphoma, rectal cancer, breast cancer, stomach cancer, pancreatic cancer, liver cancer, lung cancer, head and neck cancer, kidney cancer, colon cancer, ovarian cancer, prostate cancer, multiple sclerosis, immunity diseases, allergic diseases, atherosclerosis, gastrointestinal disorders, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, Alzheimer's disease, stroke and coronary artery disease, Wiskott-Aldrich syndrome, myelofibrosis, and AIDS.
7. A pharmaceutical composition, comprising: (i) an effective amount of a compound of formula (I) according to claim 1 , or the optical isomers, pharmaceutically acceptable salts thereof; and (ii) pharmaceutically acceptable carriers.
8. A method for preparing the compound of claim 1 , comprising the following steps:
(1) in an inert solvent, compound Ia reacts with A-NH2 to provide compound Ib;
(2) in an inert solvent, compound Ib reacts with compound R1B(OH)2 to obtain compounds of formula I;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/478,451 US20220002318A1 (en) | 2016-12-12 | 2021-09-17 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016111413948 | 2016-12-12 | ||
CN201611141394 | 2016-12-12 | ||
PCT/CN2017/115755 WO2018108083A1 (en) | 2016-12-12 | 2017-12-12 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
US201916468902A | 2019-06-12 | 2019-06-12 | |
US17/478,451 US20220002318A1 (en) | 2016-12-12 | 2021-09-17 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/468,902 Division US11142535B2 (en) | 2016-12-12 | 2017-12-12 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor |
PCT/CN2017/115755 Division WO2018108083A1 (en) | 2016-12-12 | 2017-12-12 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220002318A1 true US20220002318A1 (en) | 2022-01-06 |
Family
ID=62557983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/468,902 Active US11142535B2 (en) | 2016-12-12 | 2017-12-12 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor |
US17/478,451 Abandoned US20220002318A1 (en) | 2016-12-12 | 2021-09-17 | Heterocyclic compound as syk inhibitor and/or syk-hdac dual inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/468,902 Active US11142535B2 (en) | 2016-12-12 | 2017-12-12 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor |
Country Status (4)
Country | Link |
---|---|
US (2) | US11142535B2 (en) |
EP (1) | EP3553065A4 (en) |
CN (1) | CN110099909B (en) |
WO (1) | WO2018108083A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021018168B1 (en) | 2019-03-21 | 2023-11-28 | Onxeo | PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER |
KR20220098759A (en) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | A method of treating cancer that has acquired resistance to a kinase inhibitor |
KR20220124176A (en) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | Substituted tetrahydrofuran as a modulator of sodium channels |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230130909A1 (en) * | 2020-04-20 | 2023-04-27 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Hpk1 inhibitor, preparation method therefor and use thereof |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5496915B2 (en) * | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6-Aryl-imidazo [1,2-a] pyrazine derivatives, methods for their preparation, and methods for their use |
PT2373169E (en) * | 2008-12-08 | 2015-10-05 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors |
US8450321B2 (en) * | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
MX2011006094A (en) * | 2008-12-08 | 2011-11-29 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors. |
US20130338142A1 (en) * | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
WO2016197987A1 (en) * | 2015-06-12 | 2016-12-15 | 杭州英创医药科技有限公司 | Heterocyclic compound serving as syk inhibitor and/or syk-hdac dual inhibitor |
CN106187919A (en) * | 2016-06-30 | 2016-12-07 | 浙江大学 | Quinazoline derivant containing hydroxamic acid side chain and preparation and application |
DE102016113002B4 (en) | 2016-07-14 | 2022-09-29 | OSRAM Opto Semiconductors Gesellschaft mit beschränkter Haftung | Devices with improved efficiency and methods of manufacturing devices |
-
2017
- 2017-12-12 EP EP17881813.4A patent/EP3553065A4/en not_active Withdrawn
- 2017-12-12 US US16/468,902 patent/US11142535B2/en active Active
- 2017-12-12 CN CN201780076943.4A patent/CN110099909B/en active Active
- 2017-12-12 WO PCT/CN2017/115755 patent/WO2018108083A1/en unknown
-
2021
- 2021-09-17 US US17/478,451 patent/US20220002318A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2018108083A1 (en) | 2018-06-21 |
US11142535B2 (en) | 2021-10-12 |
EP3553065A4 (en) | 2020-07-01 |
CN110099909A (en) | 2019-08-06 |
US20200079795A1 (en) | 2020-03-12 |
EP3553065A1 (en) | 2019-10-16 |
CN110099909B (en) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11142535B2 (en) | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | |
US11266640B2 (en) | Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor | |
US9974777B2 (en) | Tetrahydrocarboline derivative | |
US8304408B2 (en) | Wnt signaling inhibitors, and methods for making and using them | |
US20210300869A1 (en) | Modulators of ror-gamma | |
AU2003235741B2 (en) | Deazapurines and uses thereof | |
US9738630B2 (en) | Inhibitors of lysine methyl transferase | |
US10676438B2 (en) | KCNQ2-5 channel activator | |
JP2008540396A (en) | 2-Amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for treating viral infections such as cancer and hepatitis C | |
KR20050057408A (en) | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | |
WO2016197987A1 (en) | Heterocyclic compound serving as syk inhibitor and/or syk-hdac dual inhibitor | |
CA2681861A1 (en) | Ornithine derivative | |
AU740425B2 (en) | Modulators of proteins with phosphotyrosine recognition units | |
US20200062727A1 (en) | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
CN110551102B (en) | ALK covalent inhibitors and uses thereof | |
US10519105B2 (en) | KCNQ2-5 channel activator | |
JP3376479B2 (en) | Condensed pyrimidine derivatives, their production and use | |
US11534439B2 (en) | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | |
CN111100086B (en) | 1,3, 4-oxadiazole-2-cyclobutyl compound and preparation method thereof | |
WO2021239068A1 (en) | Heterocyclic compounds as sting modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HANGZHOU INNOGATE PHARMA CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, HANCHENG;LIU, SHIFENG;YE, XIANGYANG;AND OTHERS;REEL/FRAME:057699/0004 Effective date: 20190620 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |